annual report care world person time inspire unite people johnson johnson onthecover michelleanemployeewiththejohnsonjohnsonfamilyof scan thisqr code toview companiesenjoystimewithheryoungdaughteralexiswhile adigital version grandmotherjacquelinelooksonjohnsonjohnsonhelpspeople johnson johnson annual report allovertheworldcareforthehealthandwellbeingofthosethey loveandtolivelongerhealthierhappierliveschairmans letter shareholder sibegantocomposethisletterirealizedhowquicklymyfirstyearhas passedaschiefexecutiveofficerofjohnsonjohnsonithasbeena yearwithmanyrewardingmomentsaswellassomechallengesthough ayearoftransitionwemadesolidprogressonmanyfrontsinclude buildingoutstrategicplatformswhileestablishingexcitingnewone iamhonoredtobejusttheseventhceoinourlonghistorythislegacyof leadershipisatributetothesuccessandstabilityofjohnsonjohnsonandtothe beliefintheimportanceofourpurposeheldincommonwithusbyourshareholder oversomanydecadespersonallyiamtrulyhumbledtoleadtheincrediblytalente anddedicatedpeoplewhoworkforjohnsonjohnson onechallengeallofusintheworldtodayfacetogetherishealthandhealthcare thisistrueinbothdevelopedandemergingmarketswhencombinedwiththe rapidlychangingdemographicsofanagingpopulationagrowingmiddleclassand thepersistenceofchronicdiseasethescaleandcomplexityoftheissueismagnifie itismybeliefthatprovidinghighqualityhealthcaretopatientsandconsumer alexgorsky aroundtheworldinasustainablemannerissocietysgreatestchallengebutitisalso chairmanboardofdirectorsand thegreatesthopeforabetterfutureforeveryindividualeveryfamilyevery chiefexecutiveofficer communityandeverycountry johnsonjohnsonworksattheverycenterofthischallengeacrossthebroadestbaseofanycompanyinglobalhealthcareevery dayweareworkingtohelppeopleeverywherelivelongerhealthierandhappierliveswerecognizethatwithourgloballeadership comesaresponsibilityoneweconsideraprivilegeimpleasedwithhowwearemeetingthatresponsibilitybutimfarfromsatisfie thepassinglastfallofformerceojamesburkeremindedusallthatthesimplesetofbeliefsdefinedinourcredocanguideour companythroughallthechallengesandcomplexitiesoftheseoranytimemyoverarchinggoalasceoistoensurethatournearly employeesinmorethanoperatingcompaniesaroundtheworldwillalwaysbeunitedbyourcredoandoursingle purposecaringfortheworldonepersonatatime legacyofcare thatpurposewasatworkhereinnewjerseythehomestateofjohnsonjohnsonwhenhurricanesandyroaredthroughsomany communitieslastyearimmediatelypartneringwiththeamericanredcrosssavethechildrenamericaresandotherdisaster assistancegroupsjohnsonjohnsonwasabletohelpprovideaidandreliefweprovidedmorethanfirstaidkitsthatwere usedbyemergencyrespondersweprovidedtheblanketsthatwarmedfamiliesinsheltersweweretherewithmorethanmillion infundingrespondingtothegovernorsofthreestatesinthisregionmostimportantlyourpeoplewerethereintheirown communitiesimmediatelyandwithouthesitationtheywereonthefrontlinesofresponseandreliefeffortswhereverandhowever theycould itisthisexampleofcaringbyindividualsthatinspirescaringinthewholecommunityandremindsmeofhowfirmlyand fundamentallycompassioniswovenintothefabricofourculturethislegacyofcaringcontinuesaswerenewourcommitmentto philanthropyandcitizenshipallovertheworldwewilllooktogobeyondreliefandrebuildingandexploreprogramsthatwillmake communitiesmoreresilientandpreparethemtoendureanykindofdisasterbeitnaturaloreconomic businessresult oursolidbusinessresultsinwereachievedwhilecontinuingtodelivermeaningfulinnovationinhealthcaretopatientsand customer wegeneratedsignificantcashflowandmaintainedouraaacreditratingimportantlywecontinuedourtrackrecordof consistentperformancewithstraightyearsofadjustedearningsincreasesandconsecutiveyearsofdividendincreases johnsonjohnsonisoneofonlysixcompaniesinthestandardpoorsindextoachievethatrecord inourpharmaceuticalsbusinesssegmentourresultsincludedstronggrowthofkeyproductsandsuccessfulnewlaunche asaresultofourcontinuingcommitmenttoresearchanddevelopmentcollaborationandinnovationweexpectto maintainstrongmomentumwecontinuetomakeimportantinvestmentsinbuildingstrategicpartnershipsandadvance ourpipelinepositioninguswelltodeliversustainablegrowthinandbeyond chairmansletter theadditionofsynthesinctoourfamilyofcompaniesmarkedthelargestacquisitioninourhistoryandcombine withdepuycreatestheworldslargestmostcomprehensiveorthopaedicsandneurologicsbusinessthedepuysynthe companieswewillcontinuetheexcitingintegrationofsynthesintoourmedicaldevicesanddiagnosticsbusiness segmentinthecomingyear inourconsumerbusinesssegmentwewillcontinuerestoringareliablesupplyofourmcneiloverthecounter medicinestheworktobringourplantsfullyonlineisprogressingweexpecttoreturnaconsistentsupplyofkey productstothemarketoverthecourseofwearedefinitelymakinggoodprogresshoweverwemustmovefrom goodtogreatthisyear moredetailsontheprogressofourthreebusinesssegmentscanbefoundinthebusinesssegmenthighlightssectionofthis annualreport ensuringrobustgrowth withinthecontextofourcredoandstrategicframeworktherearespecificareasoffocusforjohnsonjohnsonourgrowth driversthatwillhelpensurerobustgrowthforthefuture firstisourcommitmenttoinnovationtocreatevaluenotjustinnovationinproductsandservicesbutineverythingwe doandeverywhereweoperateweneedaconstantflowofnewideasanddifferentapproachestomeetthechallengesand opportunitiesofthefuture secondourglobalreachmustbebroughttolifewithalocalfocusthatputscriticaldecisionmakingwheretheneedsare andwhereourglobalresourceslivewebelieveourcommitmenttodecentralizedmanagementprovidesacompetitive advantageinallofourbusinessesandallofourmarket thirdwewillhavealaserfocusonexcellenceinexecutionacrossourenterprisewehavebuiltgreateraccountabilityfor qualityintotherequirementsforallofourleadersthishasstrengthenedqualityandcomplianceattheenterpriselevelby takingspecificstepstoreducevariationandincreasegovernanceweveredefinedstandardsandprocessesinoursupply chaintomostimportantlyimprovethelevelofexecutionandtodeliverefficienciesthatcanfreeresourcesfor investment fourthwewillcontinuetofosterapurposedrivenorganizationanddevelopleadershipateverylevelofourcompany thisisessentialforustodeliverontheresponsibilitiesthatcomealongwithourgloballeadership addressingaglobalchallenge ourbroadbaseinhealthcaregivesusauniqueperspectiveontheneedsfearsfrustrationsandhopesofconsumerspatientstheir familiesandhealthprofessionalsworldwideibelievethatahealthierworldisnotjustahappierworldbutalsoonethathasmuch greatereconomicstabilityandprovidesafoundationforindividualandsocietaladvancementimveryproudoftheprogresswe havemadetowardourpurposeofcaringfortheworldonepersonatatimebutallofusarekeenlyawareofthegapsthatstillexist intheworld forexamplethereisagapinaccesstobasichealthcarewhetherbecauseofalackoftrainedprofessionalsinadequate infrastructureorculturalobstaclesaddressingthisgapisakeylongtermgoalforusastheleaderinglobalhealthcare thereisagapinadequatementalhealthcareservicesthishascometopublicattentioninglaringexamplesofrecenttragediesin theunitedstatesagainthisgapmaybearesultofalackoftrainedprofessionalsorthestigmathattoooftenpreventspeoplefrom seekinghelp thereisagapinpreventivemedicinethatoftenfocusessocietiesonsickcareratherthanhealthcarethisisaparticularfocus formeandforallofusatjohnsonjohnsonnotonlybecauseofthedepthoftheproblembutalsobecauseofthescopeofthe opportunity canweclosethesegapswearecommittedtoconveningadialoguethatrecognizesandaddressesthesesignificantgapsin caringwewillworkwithcommunitiesandlocalpartnersaroundtheworldtotakemeaningfulactiontoimprovepeopleslive thatsaglobalchallengeweaimtoaddressworkingtogetherwecanandwemust ourinspiration thechallengeswefaceinthiseverchanginghealthcarelandscapewillrequiretimevigilanceanddedicationtosolveallofushere atjohnsonjohnsonrealizeweareonajourneyeverydaythoughiaminspiredbyyetanotherstoryofhowwehavedeliveredon ourcredo johnsonjohnsonannualreportthisyearwevecreatedafullyinteractivedigitalonlineannualreportwhereyoucanfindourstoriesofcaringhereareafew examplestogiveyouanideaofthebreadthofthismosaic ashaisamotherraisingchildreninbangladeshwherereliablehealthinformationcansometimesbehardtofindafter strugglingwiththehealthofherfirstchildashaisnowbetterpreparedtotakecareofhernewdaughterthankstovital healthmessagesdeliveredbytexttohermobilephonejohnsonjohnsonandbabycenter arefoundingpartnersina uniquecollaborationtoimprovethelivesofpregnantwomennewmothersandtheirfamiliesindevelopingcountrie forbillreachinghisthbirthdaywasmorethanamilestoneafteradiagnosisofprostatecancerseveralyearsagoanda seriesoftreatmentshedidntknowwhatwouldlieaheadnowhesonzytiga abirateroneacetateandhe spendingcherishedtimewiththepeoplehelovesandtrulycelebratingthatthbirthday braydonisanormalteenagerinmanywayshelovestohangoutwithhisfriendsplaygolfdoworkwithhisdadallthis despitebeingbornwithseverescoliosisthatcausedhisspinetocurvefusedhisribsandthreatenedtoleavehim wheelchairboundandunabletobreathewithouthelpthankstotheinnovativeveptr procedurefromdepuy synthesspinebraydoncangoaboutlivinglifetothefull youcanfindtheseandotherstoriesofcaringaswellasmuchmoreatwwwannualreportjnjcomihopeyoulllikethese storiessomuchthatyoulldecidetosharethemandourdigitalannualreportwithfamilyandfriend mycommitmenttoyou ourleadershipinhealthcarehasbeenmadepossiblebythebeliefinourmissionthatyousharewithusiamcommittedto continuingtheproudtraditionofjohnsonjohnsonasapurposeledorganizationcallingonthegreatrangeanddiversityofour worldwidetalentandcapabilitieswewillfurtherdedicateourselveseverydaytotheresponsibilitiesdefinedinourcredothefirst beingourresponsibilitytothedoctorsnursesandpatientsthemothersandfathersandallwhouseourproductseverydaywell alsocontinueourcommitmenttoouremployeesandtothecommunitiesinwhichweoperateandproudlycallhomeandtoyou ourvaluedshareholderswhohaveplaceyourconfidenceandtrustinus thisisourlegacyatjohnsonjohnsonatlastyearsannualshareholdermeetingidescribedmyselfasarealisticoptimistand despiteourchallengesifirmlybelievethereisnocompanybetterpositionedtoberecognizedastheworldsleaderinhealthcare sincerely alexgorsky chairmanboardofdirectorsandchiefexecutiveofficer march excludesspecialitem chairmansletter business segment highlight johnsonjohnsondeliveredsolidresultsinreflectingcontinuedsalesmomentuminmanypartsofourbusiness drivenbyourfocusondeliveringmeaningfulinnovationinhealthcaretopatientsandcustomersourresultsincluded stronggrowthofkeyproductssuccessfulnewproductlaunchesandtheadditionofsynthestoourfamilyofcompanie inadditionwecontinuedtomakeimportantinvestmentsbuildingstrategicpartnershipsandinadvancingourpipeline positioninguswellfordeliveringsustainablegrowth pharmaceutical segment sale medical device diagnostic consumer segment sale sale therapeutic area billion dollar segment sale sale major franchise billion dollar sale billion sale major franchise billion dollar sale billion sale change sale billion sale change total sale change total operational total operational h er operational vi io n care card c v aa r ecular women health will u n h ec rare b b r e oncology surgical care diabetes care oral care imm u n logy diagnostic neu r os c ience speci l ty surgery k c previennfteciotnioont otc infect u disease ort h p edics nu r io nals operational exclude impact currency exclude net impact synthe acquisition mdd rounded visual accuracy total change orthopaedic total change pharmaceutical withbillioninworldwidesalesinwearetheeighthlargestpharmaceuticalsbusinessintheworldandthe sixthlargestbiotechbusinessprimarycontributorstostrongoperationalgrowthofpercentincluderemicade infliximababiologicapprovedforthetreatmentofanumberofimmunemediatedinflammatorydisease velcade bortezomibatreatmentformultiplemyelomaprezista darunaviratreatmentforhivanda numberofrecentlylaunchedproduct weareacceleratinggrowthwhileensuringgreateraccessandreimbursementbyimplementingstronglaunch programsforrecentlyapprovedproductsincludingzytiga abirateroneacetateanoraloncedailymedicationfor useincombinationwithprednisoneforthetreatmentofmetastaticcastrationresistantprostatecancerinvega sustenna xeplion paliperidonepalmitateaoncemonthlylongactinginjectableatypicalantipsychoticfor treatmentofschizophreniainadultsincivo telapreviradirectactingantiviralproteaseinhibitorforthetreatment ofgenotypechronichepatitiscvirusincombinationwithpeginterferonalfaandribavirininadultsstelara ustekinumababiologicapprovedforthetreatmentofadultswithmoderatetosevereplaquepsoriasisxarelto rivaroxabananoralanticoagulantandsimponi golimumababiologicapprovedtotreatadultswithmoderately toseverelyactiverheumatoidarthritisraactivepsoriaticarthritisandactiveankylosingspondylitis business segmenthighlight salesresultswerenegativelyimpactedbygenericcompetitionforlevaquin levofloxacinatreatmentfor bacterialinfectionsandthemanufacturingsuspensionatathirdpartysupplierfordoxil doxorubicinhcl liposomeinjectioncaelyx pegylatedliposomaldoxorubicinhydrochlorideamedicationtotreatovarian andothercancer indecembertheusfoodanddrugadministrationfdagrantedacceleratedapprovalforsirturo bedaquilinetabletsforthetreatmentofpulmonarymultidrugresistanttuberculosisaspartofcombinationtherapy inadultsitiscurrentlyunderreviewbythreeregulatorybodiesincludingtheeuropeanmedicinesagencyeustate foodanddrugadministrationchinaandmedicinescontrolcouncilsouthafricathefdaandtheeuropean commissionalsoapprovedanexpandedindicationforzytiga abirateroneacetateincombinationwith prednisoneallowingfortheusebeforechemotherapyinthetreatmentofmetastaticcastrationresistantdisease innovemberthefdaapprovedadditionalindicationsforxarelto rivaroxabanforthetreatmentofdeep veinthrombosisdvtandorpulmonaryembolismpeandtoreducetheriskofrecurrenceofdvtandpe followinginitialtreatmentinadditionthefdaapprovedanewmgtabletofprezista darunavirfor oncedailyoraladministrationforthetreatmentofhumanimmunodeficiencyvirushivintreatmentnaive andtreatmentexperiencedadultpatientswithnodarunavirresistanceassociatedmutation inaugustthefdaapprovedthesupplementalnewdrugapplicationfornucynta ertapentadol extendedreleasetabletsforthemanagementofneuropathicpainassociatedwithdiabeticperipheralneuropathy inadultsinseptembertheeuropeancommissionapprovedthemarketingauthorizationfordacogen decitabineforthetreatmentofadultpatientsageyearsandabovewithnewlydiagnoseddenovoor secondaryacutemyeloidleukemiaandforthesubcutaneousadministrationofvelcade bortezomibforthe treatmentofmultiplemyeloma wehaveanexcitingandlatestagepipelineofdifferentiatedmedicinesnewdrugapplicationsarepresently underreviewintheunitedstatesandintheeuropeanunionseekingapprovalforinvokanacanagliflozin ourfirstpharmaceuticaltreatmentforpatientswithtypediabetesadditionalsubmissionsincludeda supplementalbiologicslicenseapplicationtothefdaandatypeiivariationtotheeuropeanmedicine agencyrequestingapprovalofstelara ustekinumabforthetreatmentofadultswithactivepsoriaticarthritis andofsimponi golimumabforthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitisa biologicslicenseapplicationwasalsosubmittedtothefdaseekingapprovalofintravenousivgolimumab forthetreatmentofmoderatelytoseverelyactivera proposedtradename medicaldevicesanddiagnostics withbillioninworldwidesalesinourmedicaldevicesanddiagnosticsmddbusinessisthelargest medicaltechnologybusinessintheworldoperationalgrowthwaspercentsalesincludedtheimpactofthe recentlycompletedacquisitionofsynthesincwhichcontributedpercenttoworldwidemddsegment operationalsalesgrowthnetofthedivestitureofthedepuytraumabusinessprimarycontributorstooperational growthweresalesfromtherecentlycompletedacquisitionofsynthesincintheorthopaedicsbusinessanumberof productsinthespecialtysurgerybusinesselectrophysiologyproductsinthecardiovascularcarebusinessof biosensewebsterincdisposablecontactlensesfromvistakondivisionofjohnsonjohnsonvisioncareinc whileoverallmarketgrowthhasslowedwevebeenfocusingonbuildingourmarketleadershippositionand weholdnoornopositionsinpercentofourkeyplatform wecontinuetoinvestforlongtermsustainablegrowthandcompletedthelargestacquisitioninourhistory withsynthesinjunedepuyandsynthesjoinedtoformtheworldslargestmostcomprehensiveorthopaedic andneurologicsorganizationatotalsolutionsbusinessdepuysynthesoffersanunparalleledbreadthanddepth ofproductsservicesandprogramsintheareasofjointreconstructiontraumaspinesportsmedicine neurologicalcraniomaxillofacialpowertoolsandbiomaterialsandhastheopportunitytocontributeingreater waystomeettheneedsoftodaysdynamichealthcareenvironment inthefdaapprovedevarrest fibrinsealantpatchanovelproductthatrapidlyandreliablyaidsin stoppingproblematicbleedingduringsurgerythefdaalsoapprovedthesmart control vascular stentsystemsforuseinthesuperficialfemoralarteryandortheproximalpoplitealarterytheharmonic ace shearswithadaptivetissuetechnologystrengtheningourpositioninthefastgrowingenergymarket wasalsoapprovedbythefdain johnsonjohnson annual report earlierintheyearethiconendosurgeryincreceivedanapprovableletterforthesedasys systema computerassistedpersonalizedsedationsystemfromthefdascenterfordevicesandradiologicalhealthin additionbiosensewebstersthermocool smarttouch contactforcesensingcatheterreceivedce markclearanceineuropethecatheterprovidesrealtimeinformationaboutthepreciseamountanddirectionof theforcebeingappliedduringcardiacablationprocedure wereexpandingourglobalpresencewithstronggrowthinemergingmarketsandaswelooktothefuture wereadvancinginnovativenewproductsinourpipelinecontinuingtotakeadisciplinedapproachtomanage ourportfolioandadaptingourbusinesstothechangingmarketplace consumer withbillioninworldwidesalesinourconsumerbusinessisthesixthlargestconsumerhealthcare businessintheworldoperationalgrowthwaspercentweremaincommittedtostrengtheningtheconsumer businessstartingbycontinuingtorestoreareliablesupplyofourmcneiloverthecounterotcproductstothe usmarket meanwhilepositivecontributorstooperationalresultsweresalesofupperrespiratoryotcproductsoutside theusinternationalsalesoflisterine oralcareproductsandussalesofneutrogena skincare product ourinvestmentsforgrowthinconsumerwillbepredicatedonafocusedproductportfolioapproachtodeliver sciencebasedproductswithlocalmarketinsightsprofessionalendorsementsandcommercialexcellence wehavetakenstepstoreshapeourportfolioandhavedivestednonstrategicproductsorbrandswearealso investingingrowthandexpansioninemergingmarketsthroughtheacquisitionofmarketspecificbrandslike doktormom coughcoldproductsinrussiaandshanghaielskermotherbabycoltdinchinawere alsocontinuingtoleveragethestrengthofouriconicbrandslikejohnson babyandneutrogena regardingmcneilwerecontinuingtooperateinaccordancewiththeconsentdecreeweveachievedall commitmentstodateundertheremediationworkplanwhichwasapprovedbythefdaintheworkto bringourplantsfullyonlineisprogressingweexpecttoreturntoaconsistentsupplyofkeyproductstothe marketoverthecourseofoureffortscontinuetobeintheinterestofservingcustomersconsistentwiththe responsibilitiesoutlinedinourcredo noteonforwardlookingstatement thisannualreportcontainsforwardlookingstatementsasdefinedintheprivatesecuritieslitigationreformactof thereaderiscautionednottorelyontheseforwardlookingstatementsthesestatementsarebasedoncurrentexpectationsof futureeventsifunderlyingassumptionsproveinaccurateorunknownrisksoruncertaintiesmaterializeactualresultscould varymateriallyfromtheexpectationsandprojectionsofjohnsonjohnsonrisksanduncertaintiesincludebutarenotlimite togeneralindustryconditionsandcompetitioneconomicfactorssuchasinterestrateandcurrencyexchangeratefluctuation technologicaladvancesnewproductsandpatentsattainedbycompetitorschallengesinherentinnewproductdevelopment includingobtainingregulatoryapprovalssignificantadverselitigationorgovernmentactionimpactofbusinesscombination changesinbehaviorandspendingpatternsorfinancialdistressofpurchasersofhealthcareproductsandserviceschangesto governmentallawsandregulationsanddomesticandforeignhealthcarereformstrendstowardhealthcarecostcontainment increasedscrutinyofthehealthcareindustrybygovernmentagenciesmanufacturingdifficultiesordelaysandproductefficacy orsafetyconcernsresultinginproductrecallsorregulatoryactionafurtherlistanddescriptionoftheserisksuncertaintiesand otherfactorscanbefoundinexhibitofjohnsonjohnsonsannualreportonformkforthefiscalyearende decembercopiesofthisformkaswellassubsequentfilingsareavailableonlineatwwwsecgov wwwinvestorjnjcomoronrequestfromjohnsonjohnsonjohnsonjohnsondoesnotundertaketoupdateany forwardlookingstatementsasaresultofnewinformationorfutureeventsordevelopment business segmenthighlightsmanagementsdiscussionandanalysis ofresult ofoperationsandfinancialcondition organizationandbusinesssegment resultsofoperation analysisofsalesbybusinesssegment analysisofconsolidatedearningsbeforeprovisionfortaxesonincome liquidityandcapitalresource otherinformation cautionaryfactorsthatmayaffectfutureresult auditedconsolidatedfinancialstatement consolidatedbalancesheet consolidatedstatementsofearning consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflow notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporte supportingschedule summaryofoperationsandstatisticaldata shareholderreturnperformancegraph johnsonjohnsonannualreport management discussion analysis result operation financial condition organization business segment descriptionofthecompanyandbusinesssegment johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesand diagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthebabycareskincareoralcare woundcareandwomenshealthfieldsaswellasnutritionalandoverthecounterpharmaceuticalproductsandwellness andpreventionplatformstheseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutletsand distributorsthroughouttheworldthepharmaceuticalsegmentincludesproductsinthefollowingareasantiinfective antipsychoticcontraceptivegastrointestinalhematologyimmunologyinfectiousdiseasesneurologyoncologypain managementthrombosisandvaccinestheseproductsaredistributeddirectlytoretailerswholesalersandhealthcare professionalsforprescriptionusethemedicaldevicesanddiagnosticssegmentincludesabroadrangeofproduct distributedtowholesalershospitalsandretailersusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospital andclinicstheseincludeproductstotreatcardiovasculardiseaseorthopaedicandneurologicalproductsbloodglucose monitoringandinsulindeliveryproductsgeneralsurgerybiosurgicalandenergyproductsprofessionaldiagnostic productsinfectionpreventionproductsanddisposablecontactlense thecompanysstructureisbasedupontheprincipleofdecentralizedmanagementtheexecutivecommitteeof johnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategicoperationsandallocationofthe resourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesoftheconsumerpharmaceuticaland medicaldevicesanddiagnosticsbusinesssegments inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolve competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsisimportanttothecompanyssuccessinall areasofitsbusinessthisalsoincludesprotectingthecompanysportfolioofintellectualpropertythecompetitive environmentrequiressubstantialinvestmentsincontinuingresearchandinmaintainingsalesforcesinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificant expendituresforadvertisingandpromotion managementsobjective thecompanymanageswithinastrategicframeworkaimedatachievingsustainablegrowthtoaccomplishthisthe companysmanagementoperatesthebusinessconsistentwithcertainstrategicprinciplesthathaveprovensuccessful overtimetothisendthecompanyparticipatesingrowthareasinhumanhealthcareandiscommittedtoattaine leadershippositionsinthesegrowthareasthroughthedevelopmentofhighqualityinnovativeproductsandservicesnew productsintroducedwithinthepastfiveyearsaccountedforapproximatelyofsalesinbillionor ofsaleswasinvestedinresearchanddevelopmentthisinvestmentreflectsmanagementscommitmenttothe importanceofongoingdevelopmentofnewanddifferentiatedproductsandservicestosustainlongtermgrowth withmorethanoperatingcompanieslocatedincountriesthecompanyviewsitsprincipleofdecentralize managementasanassetandfundamentaltothesuccessofabroadlybasedbusinessitalsofostersanentrepreneurial spiritcombiningtheextensiveresourcesofalargeorganizationwiththeabilitytoanticipateandreactquicklytolocal marketchangesandchallenge johnsonjohnsonannualreportthecompanyiscommittedtodevelopingglobalbusinessleaderswhocanachievegrowthobjectivesbusinessesare managedforthelongterminordertosustainleadershippositionsandachievegrowththatprovidesanenduringsourceof valuetoourshareholder ourcredounifiesthemanagementteamandthecompanysdedicatedemployeesinachievingtheseobjectivesand providesacommonsetofvaluesthatserveasaconstantreminderofthecompanysresponsibilitiestoitscustomer employeescommunitiesandshareholdersthecompanybelievesthatthesebasicprinciplesalongwithitsoverall missionofimprovingthequalityoflifeforpeopleeverywherewillenablejohnsonjohnsontocontinuetobeamongthe leadersinthehealthcareindustry result operation analysisofconsolidatedsale inworldwidesalesincreasedtobillioncomparedtoanincreaseofinandadecreaseof inthesesaleschangesconsistedofthefollowe salesincreasedecreasedueto volume price currency total salesbyuscompanieswerebillioninbillioninandbillioninthisrepresentsan increaseofinanddecreasesofinandinsalesbyinternationalcompanieswere billioninbillioninandbillioninthisrepresentsincreasesofin inandintheacquisitionofsynthesincnetoftherelateddivestitureincreasedbothtotalworldwide salesgrowthandoperationalgrowthby thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively salesineuropeexperiencedadeclineofascomparedtotheprioryearincludingoperationalgrowthofoffset byanegativecurrencyimpactofsalesinthewesternhemisphereexcludingtheusachievedgrowthof ascomparedtotheprioryearincludingoperationalgrowthofandanegativecurrencyimpactofsalesinthe asiapacificafricaregionachievedgrowthofascomparedtotheprioryearincludingoperationalgrowthof andanegativecurrencyimpactof inandthecompanydidnothaveacustomerthatrepresentedormoreoftotalconsolidate revenue ushealthcarereform undertheprovisionsofthepatientprotectionandaffordablecareactandthehealthcareandeducationreconciliation actofbeginningincompaniesthatsoldbrandedprescriptiondrugstospecifiedusgovernmentprogram payanannualnontaxdeductiblefeebasedonanallocationofeachcompanysmarketshareoftotalbrandedprescription drugsalesfromtheprioryearthefullyearimpacttosellingmarketingandadministrativeexpenseswasapproximately millioninandmillioninunderthecurrentlawbeginninginthecompanywillberequire topayataxdeductibleexcisetaximposedonthesaleofcertainmedicaldevicestheexcisetaxisestimate tobebetweenmillionandwillberecordedincostofproductssoldwithinthestatementofearning thenettradesalesimpactofthehealthcarereformlegislationwasanannualreductionofapproximatelymillionand millioninandrespectivelyduetoanincreaseinsalesrebatesanddiscount johnsonjohnsonannualreport analysis sale business segment consumersegment consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionadecreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactof majorconsumerfranchisesale change dollarsinmillion vs vs otcpharmaceuticalsnutritional skincare babycare womenshealth oralcare woundcareother totalconsumersale theoverthecounterotcpharmaceuticalsandnutritionalsfranchisesaleswerebillionadecreaseoffrom salesintheusdecreasedprimarilyduetolowersalesofanalgesicsasaresultofsupplyconstraintsand competitivepressuresinnutritionalproductsstronggrowthofupperrespiratorydigestivehealthandanalgesicsproduct outsidetheuswasoffsetbynegativecurrency mcneilppcinccontinuestooperateunderaconsentdecreesignedinwiththeusfoodanddrug administrationfdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsmcneilcontinuesto operatethemanufacturingfacilitiesinlaspiedraspuertoricoandlancasterpennsylvaniahoweverproductionvolumes fromthesefacilitiescontinuetobeimpactedbyadditionalreviewandapprovalprocessesrequiredundertheconsent decreethecompanyexpectsthistocontinuethroughoutmostofplantsoperatingundertheconsentdecreewill produceasimplifiedportfoliofocusedonkeybrandsthefortwashingtonpennsylvaniamanufacturingsiteisnotin operationatthistimemcneilcontinuestoworkontheresitingoftheproductspreviouslyproducedatthefort washingtonfacilitytootherfacilitie theskincarefranchisesaleswerebillioninadecreaseoffromincreasedsalesof neutrogenaproductsintheuswereoffsetbycompetitionandeconomicconditionsoutsidetheusthebaby carefranchisesaleswerebillionadecreaseoffromthedeclineinussalesandtheimpactof negativecurrencywaspartiallyoffsetbyincreasedsalesofhaircareandwipesoutsidetheusthewomenshealth franchisesaleswerebillionadecreaseofprimarilyduetotheimpactofthedivestitureofcertainbrandsthe oralcarefranchisesaleswereflatascomparedtotheprioryearincreasedsalesoflisterineproductsoutsidethe uswerepartiallyoffsetbycompetitivepressuresintheusthewoundcareotherfranchisesaleswerebillionin adecreaseoffromduetodivestituresandcompetitivepressuresnegativecurrencyimpactedallofthe franchise consumersegmentsalesinwerebillionanincreaseoffromaoperationaldeclinewa offsetbyapositivecurrencyimpactofusconsumersegmentsaleswerebillionadecreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrency impactof johnsonjohnsonannualreportpharmaceutical segment thepharmaceuticalsegmentachievedsalesofbillioninrepresentinganincreaseofovertheprioryear withoperationalgrowthofandanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthanda negativecurrencyimpactof majorpharmaceutical therapeuticareasales change dollarsinmillion vs vs totalimmunology remicade simponi stelara otherimmunology totalinfectiousdisease intelence levaquinfloxin prezista otherinfectiousdisease totalneuroscience concertamethylphenidate invega invegasustennaxeplion risperdalconsta otherneuroscience totaloncology doxilcaelyx velcade zytiga otheroncology totalother aciphexpariet procriteprex totalpharmaceuticalsale prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthan immunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yeartheincreasedsalesofsimponigolimumabandremicadeinfliximabwereprimarilyduetomarketgrowth andtheimpactoftheagreementwithmerckcoincmerckeffectivejulydistributionrightstoremicade andsimponiincertainterritorieswererelinquishedtothecompanybymerckadditionalcontributorstotheincrease weresalesofstelaraustekinumab infectiousdiseaseproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtothe prioryearmajorcontributorswereincivotelaprevirthecontinuedmomentuminmarketsharegrowthofprezista darunaviredurantrilpivirineandintelenceetravirinepartiallyoffsetbylowersalesoflevaquin levofloxacinfloxinofloxacinduetothelossofmarketexclusivityintheusinjune johnsonjohnsonannualreport neuroscienceproductssaleswerebillionadeclineofascomparedtotheprioryeargrowthwasimpactedby genericcompetitionforconcertamethylphenidaterazadynegalantaminerisperdalrisperidoneand duragesicfentanyltransdermalfentanyltransdermalsystemadeclineinthecompanyslongactinginjectable antipsychoticrisperdalconstarisperidonewasoffsetbystrongsalesofinvegasustennaxeplion paliperidonepalmitateandinvegapaliperidonepalmitatethecompanysussupplyanddistributionagreement withwatsonlaboratoriesinctodistributeanauthorizedgenericversionofconcertabecameeffectivemay theoriginalconcertapatentexpiredinandthepartieshavereceivedapprovalfromthefdatomanufacture andmarketagenericversionofconcertaanothergenericversionofconcertawaslaunchedondecember thiswillresultinafurtherreductioninconcertasale oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearthisgrowthwasprimarilyduetosalesofzytigaabirateroneacetateandvelcadebortezomibthisgrowth waspartiallyoffsetbylowersalesofdoxildoxorubicinhciliposomeinjectioncaelyxpegylatedliposomal doxorubicinhydrochlorideduetosupplyconstraintsfromthecompanysthirdpartymanufacturerthecompanyhas beenworkingtorestoreareliablesupplyofdoxilcaelyxfullaccessintheushasbeenrestoredanalternate manufacturingapproachwasapprovedintheeuropeanunioneuandjapanlateinandincanadainjanuaryof intheeuropeanunionthecaelyxmanagedaccessprogramwasputinplacetoensurepatientscancomplete theirfullcourseoftreatmentitwillremaininplaceuntilafullsupplyofcaelyxhasbeenrestoredinfebruarythe fdaapprovedagenericversionofdoxil otherpharmaceuticalsaleswerebillionadeclineofascomparedtotheprioryearprimarilyduetodivestiture andlowersalesofaciphexparietrabeprazolesodiumandeprexepoetinalfaprimarilyduetotheimpactof genericcompetitiontheseresultswerepartiallyoffsetbysalesgrowthofxareltorivaroxaban duringthecompanyreceivedseveralregulatoryapprovalsincludingusapprovalofanewmgtabletof prezistadarunavirforoncedailyoraladministrationforthetreatmentofhumanimmunodeficiencyvirushivin treatmentnaiveandtreatmentexperiencedadultpatientswithnodarunavirresistanceassociatedmutationsfda approvalfortheexpandeduseofxareltorivaroxabantotreatdeepveinthrombosisordvtandpulmonary embolismorpeandtoreducetheriskofrecurrentdvtandpefollowinginitialtreatmentandthefdagrante acceleratedapprovalforsirturobedaquilinetabletsforthetreatmentofpulmonarymultidrugresistanttuberculosis aspartofcombinationtherapyinadultsthefdaapprovedthesupplementalnewdrugapplicationndafor nucyntaertapentadolextendedreleasetabletsanoralanalgesictakentwicedailyforthemanagementof neuropathicpainassociatedwithdiabeticperipheralneuropathyinadultsthefdaandtheeuropeancommissionalso approvedanexpandedindicationforzytigaabirateroneacetateincombinationwithprednisoneallowingfortheuse beforechemotherapyinthetreatmentofmetastaticcastrationresistantprostatecancerinadditiontheeuropean commissionapprovedthemarketingauthorizationsfordacogendecitabineforthetreatmentofadultpatientsage yearsandabovewithnewlydiagnoseddenovoorsecondaryacutemyeloidleukemiawhoarenotcandidatesfor standardinductionchemotherapyandforthesubcutaneousadministrationofvelcadebortezomibforthetreatment ofmultiplemyeloma thecompanysubmittedseveralnewdrugapplicationsincludinganndatothefdaandmarketingauthorization applicationmaatotheeuropeanmedicinesagencyemaseekingapprovalfortheuseofcanagliflozinanoralonce dailyselectivesodiumglucosecotransportersgltinhibitorforthetreatmentofadultpatientswithtypediabete andanndaseekingapprovalforafixeddosetherapycombiningcanagliflozinandimmediatereleasemetformintotreat patientswithtypediabetesadditionalsubmissionsincludedasupplementalbiologicslicenseapplicationtothefda andatypeiivariationtotheemarequestingapprovalofstelaraustekinumabforthetreatmentofadultpatient withactivepsoriaticarthritisandabiologicslicenseapplicationtothefdarequestingapprovalofaninvestigational intravenousformulationoftheantitumornecrosisfactortnfalphasimponigolimumabforthetreatmentofadult withmoderatelytoseverelyactiverheumatoidarthritisinadditionasupplementalbiologicslicenseapplicationwa submittedtothefdaandatypeiivariationwassubmittedtotheemarequestingapprovalofsimponigolimumabfor thetreatmentofmoderatelytoseverelyactiveulcerativecolitisinadultpatientswhohavehadaninadequateresponseto conventionaltherapyincludingcorticosteroidsandmercaptopurinemporazathioprineazaorwhoareintolerant toorhavemedicalcontraindicationsforsuchtherapiesfinallyanmaawassubmittedtotheemaseekingconditional approvalfortheuseofbedaquilinetmcasanoraltreatmenttobeusedaspartofcombinationtherapyfor pulmonarymultidrugresistanttuberculosisinadult pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwithoperationalgrowthof andapositivecurrencyimpactofussaleswerebillionadecreaseofinternationalsaleswere billionanincreaseofwhichincludedoperationalgrowthandapositivecurrencyimpactof johnsonjohnsonannualreportmedicaldevicesanddiagnosticssegment themedicaldevicesanddiagnosticssegmentachievedsalesofbillioninrepresentinganincreaseof overtheprioryearwithoperationalgrowthofandanegativecurrencyimpactofussaleswerebillion anincreaseofascomparedtotheprioryearinternationalsaleswerebillionanincreaseofoverthe prioryearwithoperationalgrowthofandanegativecurrencyimpactoftheacquisitionofsynthesincnetof therelateddivestitureincreasedbothtotalsalesgrowthandoperationalgrowthforthemedicaldevicesanddiagnostics segmentby majormedicaldevicesanddiagnosticsfranchisesale change dollarsinmillion vs vs orthopaedic surgicalcare visioncare diabetescare specialtysurgery diagnostic cardiovascularcare infectionpreventionother totalmedicaldevicesanddiagnosticssale prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation theorthopaedicsfranchiseachievedsalesofbillioninaincreaseovertheprioryeargrowthwas primarilyduetosalesofnewlyacquiredproductsfromsynthesincandsalesofjointreconstructionandmiteksport medicineproductssaleswereimpactedbythedivestituresofthesurgicalinstrumentsbusinessofcodmanshurtleff incinthefiscalfourthquarterofandthedivestitureofcertainrightsandassetsrelatedtothedepuytrauma businessthepositiveimpactontheorthopaedicsfranchisetotalsalesgrowthandoperationalgrowthduetothenewly acquiredproductsfromsynthesincnetoftherelatedtraumabusinessdivestiturewa thesurgicalcarefranchisesaleswerebillioninadecreaseoffromtheprioryearlowersalesof mechanicalbreastcareandpelvicfloorproductswerepartiallyoffsetbyincreasedsalesofsuturesandendoscopy productswiththesuccessoftheechelonflexpoweredendopathstapler thevisioncarefranchiseachievedsalesofbillioninaincreaseovertheprioryearthegrowthwa drivenbyacuvuetrueyedayacuvuemoistforastigmatismanddayacuvuemoist thediabetescarefranchisesaleswerebillionadecreaseofversustheprioryearsalesgrowthinasiaand latinamericawasoffsetbythenegativeimpactofcurrency thespecialtysurgeryfranchiseachievedsalesofbillioninaincreaseovertheprioryearincremental salesfromtheacquisitionofsterilmedincsalesofbiosurgeryproductsandinternationalsalesofenergyproductswere themajorcontributorstothegrowth thediagnosticsfranchisesaleswerebillionadeclineofversustheprioryearthedeclinewasprimarilydueto lowersalesindonorscreeningduetocompetitivepressuresandthedivestitureoftherhogambusinessduringthe thirdquarterofinjanuarythecompanyannounceditisexploringstrategicalternativesfortheorthoclinical diagnosticsbusinessincludingapossibledivestiture thecardiovascularcarefranchisesaleswerebillionadeclineofversustheprioryearsaleswereimpacte bythecompanysdecisiontoexitthedrugelutingstentmarketinthesecondquarterofandlowersalesof endovascularproductsimpactedbycompetitivelaunchesandadisruptioninsupplythatwasresolvedlateinthethird quarterthedeclineinsaleswaspartiallyoffsetbystronggrowthinbiosensewebsterselectrophysiologybusiness primarilyduetothesuccessofthethermocoolcatheterlaunche theinfectionpreventionotherfranchiseachievedsalesofbillioninaincreaseovertheprioryear primarilyduetogrowthintheadvancedsterilizationbusiness johnsonjohnsonannualreport themedicaldevicesanddiagnosticssegmentachievedsalesofbillioninrepresentinganincreaseof overtheprioryearwithoperationalgrowthofandapositivecurrencyimpactofussaleswerebillion adecreaseofascomparedtotheprioryearinternationalsaleswerebillionanincreaseofoverthe prioryearwithoperationalgrowthofandapositivecurrencyimpactof analysis consolidate earning provision taxis income consolidatedearningsbeforeprovisionfortaxesonincomeincreasedbybilliontobillioninas comparedtobillioninanincreaseofearningsbeforeprovisionfortaxesonincomewerefavorable duetoincreasedgrossprofitofbillionabilliondecreaseinsellingmarketingandadministrativeexpensesdue tocostcontainmentinitiativesacrossmanyofthebusinesseslowerlitigationexpenseofbillionandlowerchargesof billionrelatedtothedepuyasrhipprogramversustheprioryearthiswaspartiallyoffsetbybillionof chargesattributabletoassetwritedownsandimpairmentofinprocessresearchanddevelopmentprimarilyrelatedtothe crucellvaccinebusinessandthediscontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivandbillion ofintegrationandcurrencycostsrelatedtotheacquisitionofsynthesincversustheprioryearincludedinwasa billionrestructuringchargenetofinventorywriteoffswhichareincludedincostofproductssoldrelatedtothe cardiovascularcarebusinessadditionallyincludedhighergainsfromdivestituresandotheritemsofbillion recordedinotherincomeexpensenet thedecreaseofascomparedtowasprimarilyduetocostsassociatedwithlitigationwhichinclude productliabilitytheimpactoftheotcanddepuyasrhiprecallsandtherestructuringexpenserelatedtothe cardiovascularcarebusinessadditionallyinvestmentspendingthefeeonbrandedpharmaceuticalproductsincurred duetotheushealthcarereformlegislationandtheintegrationcostsincludinganinventorystepupchargeassociate withtheacquisitionofcrucellcontributedtothedecreaseinearningsthiswaspartiallyoffsetbygainsfromdivestitures asapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomeinwasversusin costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselling marketingandadministrativeexpensesasapercenttosaleswereasfollow ofsale costofproductssold percentpointincreaseovertheprioryear sellingmarketingandadministrativeexpense percentpointdecreaseincreaseovertheprioryear incostofproductssoldasapercenttosalesincreasedcomparedtotheprioryearthiswasprimarilytheresultof theamortizationoftheinventorystepupchargeofbillionandamortizationofintangiblesrelatedtothesynthesinc acquisitionofbillionandongoingremediationcostsinthemcneilotcbusinesstherewasadecreaseinthe percenttosalesofsellingmarketingandadministrativeexpensesincomparedtotheprioryearprimarilyduetocost containmentinitiativesacrossmanyofthebusinessestheprioryearperiodincludedhigherinvestmentspendinginthe pharmaceuticalbusinessfornewproduct incostofproductssoldasapercenttosalesincreasedcomparedtotheprioryearthiswasprimarilyattributable toongoingremediationcostsinthemcneilotcbusinessandinventorywriteoffsduetotherestructuringofthe cardiovascularcarebusinessinadditionlowermarginsandintegrationcostsincludinganinventorystepupcharge associatedwiththeacquisitionofcrucellnegativelyimpactedcostofproductssoldpercenttosalesofsellingmarkete andadministrativeexpensesincreasedincomparedtotheprioryearprimarilyduetoinvestmentspendingaswellas thefeeonbrandedpharmaceuticalproductsincurredduetotheushealthcarereformlegislation johnsonjohnsonannualreportresearchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillion ofsale ofsale ofsale consumer pharmaceutical medicaldevicesanddiagnostic totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year asapercenttosegmentsale researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsimprovingexistingproductsaswellasensuring productefficacyandregulatorycompliancepriortolaunchthecompanyremainscommittedtoinvestinginresearchand developmentwiththeaimofdeliveringhighqualityandinnovativeproductsinworldwidecostsofresearchand developmentactivitiesincreasedbycomparedtothedecreaseinthemedicaldevicesanddiagnostic segmentwasprimarilyduetothediscontinuationoftheclinicaldevelopmentprogramforthenevosirolimuselute coronarystent inprocessresearchanddevelopmentiprdinthecompanyrecordedachargeofbillionwhich includedbillionfortheimpairmentoftheiprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentof bapineuzumabivandthepartialimpairmentoftheiprdrelatedtothecrucellvaccinebusinessintheamountof billionofthebillionimpairmentoftheiprdrelatedtothediscontinuationofthephaseiiiclinicaldevelopmentof bapineuzumabivbillionisattributabletononcontrollinginterestthesechargesrelatetodevelopmentproject whichhavebeenrecentlydiscontinuedordelaye otherincomeexpensenetotherincomeexpensenetincludesroyaltyincomegainsandlossesrelatedtothe saleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnsondevelopmentcorporation gainsandlossesonthedisposalofpropertyplantandequipmentcurrencygainsandlossesandlitigationsettlementsin thefavorablechangeofbillioninotherincomeexpensenetwasprimarilyduetolowerexpensesof billionrelatedtolitigationincludingproductliabilityandbillionforcostsrelatedtothedepuyasrhipprogram thiswaspartiallyoffsetbybillionattributedtoassetwritedownsprimarilyrelatedtothecrucellvaccinebusiness andbillionofhigherintegrationtransactionandcurrencycostsrelatedtotheacquisitionofsynthesinc intheunfavorablechangeofbillioninotherincomeexpensenetwasprimarilyduetonetlitigationwhich includesproductliabilityofbillioninascomparedtoabillionnetgainfromlitigationinadditionally ascomparedtoincludedhigherexpensesofbillionforcostsrelatedtothedepuyasrhipprogram andanadjustmentofbilliontothevalueofthecurrencyoptionanddealcostsrelatedtotheacquisitionofsynthe incincludedinwerehighergainsonthedivestituresofbusinessesofbillionascomparedto restructuringincordiscorporationasubsidiaryofjohnsonjohnsonannouncedthediscontinuationofit clinicaldevelopmentprogramforthenevosirolimuselutingcoronarystentandcessationofthemanufactureand marketingofcypherandcypherselectplussirolimuselutingcoronarystentsbytheendofthe companyrecordedapretaxchargeofbillionofwhichbillionwasincludedinthecostofproductssoldthere wasnorestructuringchargeinseenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelate totherestructure interestincomeexpenseinterestincomeindecreasedbymillionascomparedtotheprioryeardueto lowerratesofinterestearnedandloweraveragecashbalancescashcashequivalentsandmarketablesecuritiestotale billionattheendofandaveragedbillionascomparedtothebillionaveragecashbalancein thedeclineintheaveragecashbalancewasduetotheacquisitionofsynthesincpartiallyoffsetbycash generatedfromoperatingactivitie interestexpenseindecreasedbymillionascomparedtoduetoaloweraveragedebtbalancethe averagedebtbalancewasbillioninversusbillioninthetotaldebtbalanceattheendof wasbillionascomparedtobillionattheendofthereductionindebtofapproximatelybillionwas primarilyduetoareductionincommercialpaper johnsonjohnsonannualreport interestincomeindecreasedbymillionascomparedtotheprioryearduetolowerratesofinterestearne despitehigheraveragecashbalancescashcashequivalentsandmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothebillionaveragecashbalanceintheincreaseinthe averagecashbalancewasprimarilyduetocashgeneratedfromoperatingactivitiesandnetcashproceedsfrom divestiture interestexpenseinincreasedbymillionascomparedtoduetoahigheraveragedebtbalancethetotal debtbalanceattheendofwasbillionascomparedtobillionattheendofthehigheraverage debtbalanceofbillioninversusbillioninwasduetoincreasedborrowingsthecompany increasedborrowingscapitalizingonfavorabletermsinthecapitalmarketstheproceedsoftheborrowingswereuse forgeneralcorporatepurpose segmentpretaxprofit pretaxprofitsbysegmentofbusinesswereasfollow percentof segmentsale dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic total lessexpensesnotallocatedtosegment earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetail amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expenseabillionandbillioncurrencyrelatedexpensefortheacquisitionofsynthesincwasincludedinand respectively consumersegmentinconsumersegmentpretaxprofitasapercenttosaleswasversusin pretaxprofitwasunfavorablyimpactedbybillionattributedtointangibleassetwritedownsandapproximately billionduetounfavorableproductmixandremediationcostsassociatedwiththemcneilppcincconsentdecree thiswaspartiallyoffsetbycostcontainmentinitiativesrealizedinsellingmarketingandadministrativeexpensesin additionincludedhighergainsondivestituresinconsumersegmentpretaxprofitdecreasedfrom theprimarydriversofthedeclineinoperatingprofitwereunfavorableproductmixandremediationcostsassociated withtherecallofcertainotcproductspartiallyoffsetbythegainonthedivestitureofmonistat pharmaceuticalsegmentinpharmaceuticalsegmentpretaxprofitasapercenttosaleswasversus inpretaxprofitwasunfavorablyimpactedbychargesofbillionattributedtothewritedownofasset andimpairmentofinprocessresearchanddevelopmentassetsrelatedtothecrucellvaccinebusinessandtothe discontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivthiswaspartiallyoffsetbylowerlitigation expenseofbillionversustheprioryearandfavorableoperatingexpensesofbillionadditionallyinclude thegainonthedivestitureofbystolicnebivololiprightsinpharmaceuticalsegmentpretaxprofitdecrease fromtheprimarydriversofthedecreaseinthepretaxprofitmarginwerehigherlitigationexpensesrecorde intheimpactoftheushealthcarereformfeeandlowermarginsandintegrationcostsincludinganinventory stepupchargeassociatedwiththecrucellacquisitionthiswaspartiallyoffsetbygainsonthedivestituresoftheanimal healthbusinessandorthodermatologicsthegainrelatedtothecompanysearlierinvestmentincrucellandlower manufacturingcost medicaldevicesanddiagnosticssegmentinmedicaldevicesanddiagnosticssegmentpretaxprofitasa percenttosaleswasversusinthemedicaldevicesanddiagnosticssegmentpretaxprofitwas favorablyimpactedbyprofitsfromsynthessaleslowerexpensesofbillionforlitigationincludingproductliability andthedepuyasrhipprogramandbillionforresearchanddevelopmentprimarilyduetothediscontinuationof itsclinicaldevelopmentprogramforthenevosirolimuselutingcoronarystentthiswaspartiallyoffsetbyanincrease inintegrationcostsandamortizationoftheinventorystepupofbillionassociatedwiththeacquisitionofsynthe incandbillionattributedtothewritedownofintangibleassetsinadditionincludedhighergainson johnsonjohnsonannualreportdivestituresversustheprioryearduetothedivestituresofthetherakosbusinessandrhogamadditionally includedabillionrestructuringchargerelatedtothediscontinuationoftheclinicaldevelopmentprogramforthe nevosirolimuselutingcoronarystentinmedicaldevicesanddiagnosticssegmentpretaxprofitdecreased fromtheprimarydriversofthedeclineinthepretaxprofitmargininthemedicaldevicesanddiagnostic segmentwerelitigationexpensesincludingproductliabilitycostsassociatedwiththedepuyasrhipprogram restructuringexpensecostsincurredrelatedtotheacquisitionofsynthesincandincreasedinvestmentspende provisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheincreaseintheeffectivetaxrateofascomparedtowasduetolowertaxbenefit ontheimpairmentofinprocessresearchanddevelopmentintangibleassetsinlowtaxjurisdictionsincreasesintaxable incomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsandtheexclusionofthebenefitoftheusresearch developmentrdtaxcreditandthecfclookthroughprovisionsfromthefiscalyearfinancialresultstherd taxcreditandthecfclookthroughprovisionswereenactedintolawinandwereretroactivetojanuary theentirebenefitoftherdtaxcreditandthecfclookthroughprovisionswillbereflectedinthefiscalyear financialresult thetaxrateincreasedascomparedtoduetocertainusexpenseswhicharenotfullytaxdeductibleand higherusstatetaxespartiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictionsrelativetohighertax jurisdiction noncontrollinginterestachargeofbillionfortheimpairmentoftheiprdrelatedtothediscontinuationofthe phaseiiiclinicaldevelopmentofbapineuzumabivwasrecordedinofthebillionimpairmentbillionis attributabletononcontrollinginter liquidity capital resource liquiditycashflow cashandcashequivalentswerebillionattheendofascomparedwithbillionattheendofthe primaryusesofcashthatcontributedtothebilliondecreaseversustheprioryearwereapproximatelybillionnet cashusedbyinvestingactivitiesandbillionnetcashusedbyfinancingactivitiespartiallyoffsetbybillionof cashgeneratedfromoperatingactivitie cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash chargesprimarilyrelatedtodepreciationandamortizationassetwritedownsprimarilyinprocessresearchand developmentstockbasedcompensationnoncontrollinginterestanddeferredtaxprovisionreducedbybillion relatedtochangesinassetsandliabilitiesnetofeffectsfromacquisition investingactivitiesuseofbillionwasprimarilyforbillionforadditionstopropertyplantandequipmentand acquisitionsnetofcashacquiredofbillionpartiallyoffsetbynetsalesofinvestmentsinmarketablesecuritiesof billionandbillionofproceedsfromthedisposalofasset financingactivitiesuseofbillionwasfortherepurchaseofcommonstockofbillionprimarilyforthe acquisitionofsynthesincdividendstoshareholdersofbillionandnetretirementofshortandlongtermdebtof billionpartiallyoffsetbybillionofnetproceedsfromstockoptionsexercisedexcesstaxbenefit inthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketforadditionaldetail onborrowingsseenotetotheconsolidatedfinancialstatement thecompanyanticipatesthatoperatingcashflowsexistingcreditfacilitiesandaccesstothecommercialpapermarket willprovidesufficientresourcestofundoperatingneedsin concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitsrecenteconomicchallengesin italyspaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccount receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand johnsonjohnsonannualreport approximatelybillionasofjanuaryapproximatelybillionasofdecemberandapproximately billionasofjanuaryofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothe companysconsumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevice anddiagnosticscustomerswhichareinlinewithhistoricalcollectionpattern theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacte bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthetotalnettradeaccount receivablebalanceforthesecustomerswereapproximatelybillionatdecemberandbillionat januarythecompanycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepayment premiumsforcustomerswherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtrade receivableshavebeendiscountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshave beenincreasedforthesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywith thesecustomersonpaymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflow accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthedecembermarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthedecembermarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflow thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastanaorequivalentcreditratingthecounterpartie tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremote thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelythereductionindebtin ofapproximatelybillionwasprimarilyduetoareductionincommercialpaper innetcashcashandcurrentmarketablesecuritiesnetofdebtwasbillioncomparedtonetcashof billionintotaldebtrepresentedoftotalcapitalshareholdersequityandtotaldebtinand oftotalcapitalinshareholdersequitypershareattheendofwascomparedtoat yearendanincreaseof asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatement johnsonjohnsonannualreportcontractualobligationsandcommitment thecompanyscontractualobligationsareprimarilyforleasesdebtandunfundedretirementplanstherearenoother significantobligationstosatisfytheseobligationsthecompanywillusecashfromoperationsthefollowingtable summarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasofdecemberseenote andtotheconsolidatedfinancialstatementsforfurtherdetails longterm intereston unfunde debt debt retirement operating dollarsinmillion obligation obligation plan lease total total fortaxmattersseenotetotheconsolidatedfinancialstatement sharerepurchase anddividend onjulythecompanyannouncedthatitsboardofdirectorsapprovedastockrepurchaseprogramauthorize thecompanytobuybackuptobillionofthecompanyscommonstockasofjanuarythecompany repurchasedanaggregateofmillionsharesofjohnsonjohnsoncommonstockatacostofbillionandthe stockrepurchaseprogramwascompletedthecompanyfundedthesharerepurchaseprogramthroughacombinationof availablecashanddebt pursuanttotheacceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofsynthesincthe companyhasnotmadeanypurchasesofcommonstockontheopenmarketduringthefiscalthirdandfourthquartersof thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpershareinthedividendsweredistributed asfollow firstquarter secondquarter thirdquarter fourthquarter total onjanuarytheboardofdirectorsdeclaredaregularquarterlycashdividendofpersharepayableon marchtoshareholdersofrecordasoffebruarythecompanyexpectstocontinuethepracticeof payingregularcashdividend johnsonjohnsonannualreport information criticalaccountingpoliciesandestimate managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompany consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosure actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockoptions revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordeliveredand titleandriskoflosspasstothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscoupon productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsale arerecorde productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebatesthelargestbeingthemedicaidrebate provisionareestimatedbasedoncontractualtermshistoricalexperiencetrendanalysisandprojectedmarketcondition inthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarily throughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternally generatedinformation salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicesanddiagnosticssegmentaretypicallyresalablebutarenotmaterialthe companyrarelyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompany hasrangedbetweenandofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebase incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold thecompanyalsoearnsservicerevenueforcopromotionofcertainproductsforallyearspresentedservicerevenue werelessthanoftotalrevenuesandareincludedinsalestocustomersthesearrangementsareevaluatedto determinetheappropriateamountstobedeferre inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivitie amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivere basedontherelativefairvalueupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedoverthe performanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaboration reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchange toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact johnsonjohnsonannualreportbelowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendeddecemberandjanuary consumersegment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatjanuaryrecordedasacontra asset pharmaceutical segment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatjanuaryrecordedasa contraasset johnsonjohnsonannualreport medicaldevicesanddiagnosticssegment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatdecemberandmillionatjanuaryrecordedasa contraasset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitie thecompanyestimatesdeferredtaxassetsandliabilitiesbasedoncurrenttaxregulationsandrateschangesintaxlaw andratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberandjanuarythecompany foreignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionandbillion respectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpractical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyandisinsureduptocertainlimitsin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimatedadditionallythecompanyrecordsinsurancereceivableamount fromthirdpartyinsurerswhenrecoveryisprobableasappropriatereservesagainstthesereceivablesarerecordedfor estimatedamountsthatmaynotbecollectedfromthirdpartyinsurer thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue johnsonjohnsonannualreportlonglivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumption regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsexpectedsalaryincreasesandhealthcarecosttrend ratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheseratesandtheeffectaratechange wouldhaveonthecompanysresultsofoperation stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesthefairvalueofeachawardisestimatedonthedateofgrantusingtheblack scholesoptionvaluationmodelandisexpensedinthefinancialstatementsoverthevestingperiodtheinputassumptions usedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandthedividendyieldseenoteto theconsolidatedfinancialstatementsforadditionalinformation newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofdecember economicandmarketfactor thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymaker consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcern thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheunited statestheweightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproduct prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi inflationratescontinuetohaveaneffectonworldwideeconomiesandconsequentlyonthewaycompaniesoperatethe companyaccountedforoperationsinvenezuelaashighlyinflationaryinandasthepriorthreeyear cumulativeinflationratesurpassedinthefaceofincreasingcoststhecompanystrivestomaintainitsprofit marginsthroughcostreductionprogramsproductivityimprovementsandperiodicpriceincrease onfebruarythevenezuelangovernmentannouncedadevaluationofitscurrencytheeffectofthe devaluationisnotexpectedtohaveamaterialimpactonthecompanysfullyearresults thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandincomebymillion thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare product changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaye medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompany business thecompanyalsooperatesinanenvironmentwhichhasbecomeincreasinglyhostiletointellectualpropertyright genericdrugfirmshavefiledabbreviatednewdrugapplicationsandasseekingtomarketgenericformsofmostofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedinandafilingsthegenericfirmswillthen introducegenericversionsoftheproductatissueresultinginthepotentialforsubstantialmarketshareandrevenue lossesforthatproductforfurtherinformationseethediscussiononlitigationagainstfilersofabbreviatednewdrug applicationsinnotetotheconsolidatedfinancialstatement johnsonjohnsonannualreport legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertainlitigationmattersandcontinuestomonitor eachrelatedlegalissueandadjustaccrualsfornewinformationandfurtherdevelopmentsinaccordancewithaccounte standardscodificationascfortheseandotherlitigationandregulatorymatterscurrentlydisclosedfor whichalossisprobableorreasonablypossiblethecompanyisunabletodetermineanestimateofthepossiblelossor rangeoflossbeyondtheamountsalreadyaccruedthesematterscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceeding commonstockmarketprice thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompanythecompositemarketpricerangesfor johnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnsonjohnsonannualreportcautionary factor affect future result thisannualreportcontainsforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalor currentfactsandanticipateresultsbasedonmanagementsplansthataresubjecttouncertaintyforwardlooke statementsmaybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandother wordsofsimilarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsfinancialperformance thecompanysstrategyforgrowthproductdevelopmentregulatoryapprovalmarketpositionandexpenditure forwardlookingstatementsarebasedoncurrentexpectationsoffutureeventsthecompanycannotguaranteethatany forwardlookingstatementwillbeaccuratealthoughthecompanybelievesthatithasbeenreasonableinitsexpectations andassumptionsinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorthatunknownrisksor uncertaintiesmaterializeactualresultscouldvarymateriallyfromthecompanysexpectationsandprojectionsinvestors arethereforecautionednottoplaceunduerelianceonanyforwardlookingstatementsthecompanydoesnotundertake toupdateanyforwardlookingstatementsasaresultofnewinformationorfutureeventsordevelopment risksanduncertaintiesincludebutarenotlimitedtogeneralindustryconditionsandcompetitioneconomicfactorssuch asinterestrateandcurrencyexchangeratefluctuationstechnologicaladvancesnewproductsandpatentsattainedby competitorschallengesinherentinnewproductdevelopmentincludingobtainingregulatoryapprovalschallengesto patentssignificantlitigationorgovernmentactionadversetothecompanyimpactofbusinesscombinationsfinancial distressandbankruptciesexperiencedbysignificantcustomersandsupplierschangestogovernmentallawsand regulationsandusandforeignhealthcarereformstrendstowardhealthcarecostcontainmentincreasedscrutinyof thehealthcareindustrybygovernmentagencieschangesinbehaviorandspendingpatternsofpurchasersofhealthcare productsandservicesfinancialinstabilityofinternationaleconomiesandsovereignriskdisruptionsduetonatural disastersmanufacturingdifficultiesordelayscomplexglobalsupplychainswithincreasingregulatoryrequirementsand productefficacyorsafetyconcernsresultinginproductrecallsorregulatoryaction thecompanysreportonformkfortheyearendeddecemberincludesinexhibitadiscussionof additionalfactorsthatcouldcauseactualresultstodifferfromexpectationsthecompanynotesthesefactorsa permittedbytheprivatesecuritieslitigationreformactof johnsonjohnsonannualreport johnson johnson subsidiaries consolidate balance sheet atdecemberandjanuary dollarsinmillionsexceptshareandpershareamountsnote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand deferredtaxesonincomenote prepaidexpensesandotherreceivable totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligation accruedtaxesonincome totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilitie totalliabilitie shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshare commonstockparvaluepersharenoteauthorizedsharesissue share accumulatedothercomprehensiveincomenote retainedearning lesscommonstockheldintreasuryatcostnotesharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement earning dollarsandsharesinmillionsexceptpershareamountsnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopmentnote interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning addnetlossattributabletononcontrollinginter netearningsattributabletojohnsonjohnson netearningspershareattributabletojohnsonjohnsonnotesand basic diluted cashdividendspershare averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement comprehensive income dollarsinmillionsnote netearning othercomprehensiveincomelossnetoftax foreigncurrencytranslation security unrealizedholdinggainlossarisingduringperiod reclassificationstoearning netchange employeebenefitplans priorservicecostamortizationduringperiod priorservicecostcurrentyear gainlossamortizationduringperiod gainlosscurrentyear effectofexchangerate netchange derivativeshedge unrealizedgainlossarisingduringperiod reclassificationstoearning netchange othercomprehensiveincomeloss comprehensiveincome comprehensivelossattributabletononcontrollinginterestnetoftax comprehensiveincomeattributabletojohnsonjohnson thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelysecuritie millionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion foreigncurrencytranslationisnotadjustedforincometaxesasitrelatestopermanentinvestmentsininternational subsidiary seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement equity dollarsinmillionsnote accumulate treasury retain comprehensive commonstock stock total earning income issuedamount balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax balancejanuary netearningsattributabletojohnsonjohnson cashdividendspaid employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththe acquisitionofsynthesinc repurchaseofcommonstock othercomprehensiveincomenetoftax balancedecember includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement cash flow dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfromoperatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation noncontrollinginterest assetwritedownsandimpairment deferredtaxprovision accountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisition increaseinaccountsreceivable increaseininventorie increaseinaccountspayableandaccruedliabilitie increaseinothercurrentandnoncurrentasset decreaseincreaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivitie additionstopropertyplantandequipment proceedsfromthedisposalofasset acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment otherprimarilyintangible netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsexcesstaxbenefit netcashusedbyfinancingactivitie effectofexchangeratechangesoncashandcashequivalent decreaseincreaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceed conversionofdebt acquisition fairvalueofassetsacquire fairvalueofliabilitiesassumedandnoncontrollinginterest netfairvalueofacquisition lessissuanceofcommonstockassociatedwiththeacquisitionofsynthesinc netcashpaidforacquisition seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportnote consolidated financial statement summaryofsignificantaccountingpolicie principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminate descriptionofthecompanyandbusinesssegment thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesand diagnosticstheconsumersegmentincludesabroadrangeofproductsusedinthebabycareskincareoralcare woundcareandwomenshealthfieldsaswellasnutritionalandoverthecounterpharmaceuticalproductsandwellness andpreventionplatformstheseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutletsand distributorsthroughouttheworldthepharmaceuticalsegmentincludesproductsinthefollowingareasantiinfective antipsychoticcontraceptivegastrointestinalhematologyimmunologyinfectiousdiseasesneurologyoncologypain managementthrombosisandvaccinestheseproductsaredistributeddirectlytoretailerswholesalersandhealthcare professionalsforprescriptionusethemedicaldevicesanddiagnosticssegmentincludesabroadrangeofproduct distributedtowholesalershospitalsandretailersusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospital andclinicstheseincludeproductstotreatcardiovasculardiseaseorthopaedicandneurologicalproductsbloodglucose monitoringandinsulindeliveryproductsgeneralsurgerybiosurgicalandenergyproductsprofessionaldiagnostic productsinfectionpreventionproductsanddisposablecontactlense newaccountingpronouncement recentlyadoptedaccountingpronouncement duringthefiscalfirstquarterofthecompanyadoptedthefinancialaccountingstandardsboardfasbguidance andamendmentsissuedrelatedtogoodwillimpairmenttestingundertheamendmentsinthisupdateanentityhasthe optiontofirstassessqualitativefactorstodeterminewhethertheexistenceofeventsorcircumstancesleadstoa determinationthatitismorelikelythannotthatthefairvalueofareportingunitislessthanitscarryingamountifafter assessingthetotalityofeventsorcircumstancesanentitydeterminesitisnotmorelikelythannotthatthefairvalueofa reportingunitislessthanitscarryingamountthenperformingthetwostepimpairmenttestisunnecessaryhoweverifan entityconcludesotherwisethenitisrequiredtoperformthefirststepofthetwostepimpairmenttestthisupdate becameeffectiveforannualandinterimgoodwillimpairmenttestsperformedforfiscalyearsbeginningafterdecember theadoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsor financialposition duringthefiscalfirstquarterofthecompanyadoptedthefasbamendmenttothedisclosurerequirementsfor presentationofcomprehensiveincometheamendmentrequiresthatallnonownerchangesinstockholdersequitybe presentedeitherinasinglecontinuousstatementofcomprehensiveincomeorintwoseparatebutconsecutive statementsthisguidancebecameeffectiveretrospectivelyfortheinterimperiodsandannualperiodsbeginningafter december duringthefiscalfirstquarterofthecompanyadoptedthefasbamendmentstodisclosurerequirementsforfair valuemeasurementtheseamendmentsresultinconvergenceoffairvaluemeasurementanddisclosurerequirement betweenusgenerallyacceptedaccountingprinciplesgaapandinternationalfinancialreportingstandardsifrs thisguidancebecameeffectiveprospectivelyfortheinterimperiodsandannualperiodsbeginningafterdecember theadoptionofthisstandarddidnothaveamaterialimpactonthecompanysresultsofoperationscashflowsor financialposition johnsonjohnsonannualreport recentlyissuedaccountingstandard notadoptedasofdecember duringthefiscalthirdquarterofthefasbissuedguidanceandamendmentsrelatedtotestingindefinitelive intangibleassetsforimpairmentundertheamendmentsinthisupdateanentityhastheoptiontofirstassessqualitative factorstodeterminewhethertheexistenceofeventsorcircumstancesindicatesthatitismorelikelythannotthatthe indefinitelivedintangibleassetisimpairedifafterassessingthetotalityofeventsandcircumstancesanentityconclude thatitisnotmorelikelythannotthattheindefinitelivedintangibleassetisimpairedthentheentityisnotrequiredto determinethefairvaluehoweverifanentityconcludesotherwisethenitisrequiredtodeterminethefairvalueofthe indefinitelivedintangibleassetandperformthequantitativeimpairmenttestanentityalsohastheoptiontobypassthe qualitativeassessmentforanyindefinitelivedintangibleassetinanyperiodandproceeddirectlytoperformingthe quantitativeimpairmenttestthisupdatebecameeffectiveforannualandinterimimpairmenttestsperformedforfiscal yearsbeginningafterseptember howeverearlyadoptionispermittedtheadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthe companysresultsofoperationscashflowsorfinancialposition infebruarythefasbissuedguidancerelatedtoadditionalreportinganddisclosureofamountsreclassifiedoutof accumulatedothercomprehensiveincomeociunderthisnewguidancecompanieswillberequiredtodisclosethe amountofincomeorlossreclassifiedoutofocitoeachrespectivelineitemontheincomestatementofwherenet incomeispresentedtheguidanceallowscompaniestoelectwhethertodisclosethereclassificationeitherinthenotesto thefinancialstatementsoronthefaceoftheincomestatementthisupdateiseffectiveforannualandinterimreporting periodsforfiscalyearsbeginningafterdecembertheadoptionofthisstandardisnotexpectedhaveamaterial impactonthecompanysresultsofoperationscashflowsorfinancialposition cashequivalent thecompanyconsiderssecuritieswithmaturitiesofthreemonthsorlesswhenpurchasedtobecashequivalent investment shorttermmarketablesecuritiesarecarriedatcostwhichapproximatesfairvalueinvestmentsclassifiedasavailablefor salearecarriedatestimatedfairvaluewithunrealizedgainsandlossesrecordedasacomponentofaccumulatedother comprehensiveincomelongtermdebtsecuritiesthatthecompanyhastheabilityandintenttoholduntilmaturityare carriedatamortizedcostmanagementdeterminestheappropriateclassificationofitsinvestmentindebtandequity securitiesatthetimeofpurchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompany periodicallyreviewsitsinvestmentsinequitysecuritiesforimpairmentandadjuststheseinvestmentstotheirfairvalue whenadeclineinmarketvalueisdeemedtobeotherthantemporaryiflossesonthesesecuritiesareconsideredtobe otherthantemporarythelossisrecognizedinearning propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheasset buildingandbuildingequipment year landandleaseholdimprovement year machineryandequipment year thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflow johnsonjohnsonannualreportrevenue recognition thecompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss passtothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscouponsproductreturnsand discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorde productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebatesthelargestbeingthemedicaidrebate provisionareestimatedbasedoncontractualtermshistoricalexperiencetrendanalysisandprojectedmarketcondition inthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarily throughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternally generatedinformation salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnsaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewithusgaap guidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsalesvaluesales returnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsforcertain franchisesinthemedicaldevicesanddiagnosticssegmentaretypicallyresalablebutarenotmaterialthecompany rarelyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyha rangedbetweenandofannualsalestocustomersduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebase incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare soldthecompanyalsoearnsservicerevenueforcopromotionofcertainproductsandincludesitinsalestocustomer thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferre shippingandhandle shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresente inventory inventoriesarestatedatthelowerofcostormarketdeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassesse annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedaswasthecaseforcertain indefinitelivedintangibleassetsinthefiscalsecondandthirdquartersofpurchasedinprocessresearchand developmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompletedatwhich pointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpointthe intangibleassetwillbewrittenofforpartiallyimpaire intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstrument asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement johnsonjohnsonannualreport determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearning orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instrument productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationtheaccrualsare adjustedperiodicallyasadditionalinformationbecomesavailable asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyandi insureduptocertainlimitsinadditiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurance coverageareaccruedwhenlossesareprobableandamountscanbereasonablyestimatedbasedontheavailabilityof priorcoveragereceivablesforinsurancerecoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscounte basiswhenitisprobablethatarecoverywillberealizedasappropriatereservesagainstthesereceivablesarerecorded forestimatedamountsthatmaynotbecollectedfromthirdpartyinsurer concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitsrecenteconomicchallengesin italyspaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccount receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofdecemberand approximatelybillionasofjanuaryapproximatelybillionasofdecemberandapproximately billionasofjanuaryofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothe companysconsumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevice anddiagnosticscustomerswhichareinlinewithhistoricalcollectionpattern theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacte bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthetotalnettradeaccount receivablebalanceforthesecustomerswereapproximatelybillionatdecemberandbillionat januarythecompanycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepayment premiumsforcustomerswherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtrade receivableshavebeendiscountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshave beenincreasedforthesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywith thesecustomersonpaymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredupfrontandmilestonepaymentsmadetothirdpartiesin connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful lifeoftherelatedproductamountscapitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulate amortization johnsonjohnsonannualreportthecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormorepartie includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract developmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollow naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomer royaltiesmilestonespaidtocollaborativepartner costofgoodssold postregulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidate researchanddevelopmentexpense advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively incometaxe incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedoncurrenttaxregulationsandrateschangesintaxlawsandratesmay affectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atdecemberandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatdecemberandjanuarythecompany foreignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsofbillionandbillion respectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational subsidiarieswheretheearningsareconsideredtobepermanentlyreinvestedthecompanyintendstocontinueto reinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatetheseearningsto theusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompanydoesnot determinethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnotpracticable seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe johnsonjohnsonannualreport netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimate thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxesdepreciation amortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresultsmayormaynot differfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks aswasthecaseinandwillbethecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation cashcashequivalentsandcurrentmarketablesecuritie attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof dollarsinmillion cash governmentsecuritiesandobligation corporatedebtsecuritie moneymarketfund timedeposit totalcashcashequivalentsandcurrentmarketablesecuritie theestimatedfairvaluewasthesameastheamortizedcostasofdecembertheestimatedfairvaluewa millionasofjanuaryreflectingamillionunrealizedgainingovernmentsecuritiesandobligation asofdecembercurrentmarketablesecuritiesconsistedofmillionandmillionofgovernment securitiesandobligationsandcorporatedebtsecuritiesrespectively asofjanuarycurrentmarketablesecuritiesconsistedofmillionandmillionofgovernment securitiesandobligationsandcorporatedebtsecuritiesrespectively fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinput thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastanaorequivalentcreditrate johnsonjohnsonannualreport inventory attheendofandinventorieswerecomprisedof dollarsinmillion rawmaterialsandsupplie goodsinprocess finishedgood totalinventorie asofdecembertheremaininginventorystepuprelatedtothesynthesincacquisitionisapproximately million propertyplantandequipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillion landandlandimprovement buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinandwasbillion billionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulate depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearning intangibleassetsandgoodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillion intangibleassetswithdefinitelive patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelive trademark purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelive totalintangibleassetsnet johnsonjohnsonannualreport goodwillasofdecemberandjanuaryasallocatedbysegmentofbusinesswasasfollow meddevice dollarsinmillion consumer pharmaceutical diagnostic total goodwillatjanuary acquisition currencytranslationother goodwillatjanuary acquisition currencytranslationother goodwillatdecember theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetswasmillion millionandmillionbeforetaxforthefiscalyearsendeddecemberjanuaryandjanuary respectivelytheestimatedamortizationexpenseforthefivesucceedingyearsapproximatesmillionbefore taxperyearamortizationexpenseisincludedincostofproductssold intangibleassetsandgoodwillincreasedbybillionandbillionrespectivelybasedonthepurchaseprice allocationforthesynthesincacquisitionseenotetotheconsolidatedfinancialstatementsforadditionaldetailson thesynthesincacquisitiontheincreaseinintangibleassetswaspartiallyoffsetbybillioninintangibleassetwrite downsandabillionimpairmentofpurchasedinprocessresearchanddevelopmentprimarilyrelatedtothe discontinuationofthephaseiiiclinicaldevelopmentofbapineuzumabivandthepartialimpairmentrelatedtothecrucell vaccinebusiness fairvaluemeasurement thecompanyusesforwardexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarilyrelatedto theforeignexchangeratechangesoffutureintercompanyproductandthirdpartypurchasesofrawmaterial denominatedinforeigncurrencythecompanyalsousescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedgesthecompanyalsouse forwardexchangecontractstomanageitsexposuretothevariabilityofcashflowsforrepatriationofforeigndividend thesecontractsaredesignatedasnetinvestmenthedgesadditionallythecompanyusesforwardexchangecontractsto offsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforwardexchangecontractsarenotdesignate ashedgesandthereforechangesinthefairvaluesofthesederivativesarerecognizedinearningstherebyoffsettingthe currentearningseffectoftherelatedforeigncurrencyassetsandliabilitiesthecompanydoesnotenterintoderivative financialinstrumentsfortradingorspeculativepurposesorcontaincreditriskrelatedcontingentfeaturesorrequirement topostcollateralonanongoingbasisthecompanymonitorscounterpartycreditratingsthecompanyconsiderscredit nonperformancerisktobelowbecausethecompanyentersintoagreementswithcommercialinstitutionsthathaveat leastanaorequivalentcreditratingasofdecemberthecompanyhadnotionalamountsoutstandingfor forwardforeignexchangecontractsandcrosscurrencyinterestrateswapsofbillionandbillionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateintothederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectivechangesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransactiongainslossesonnetinvestment hedgesareaccountedforthroughthecurrencytranslationaccountandareinsignificantonanongoingbasisthe companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesinthecashflowsof hedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinue hedgeineffectivenessifanyisincludedincurrentperiodearningsinotherincomeexpensenet asofdecemberthebalanceofdeferrednetgainsonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountrelatedtoforeignexchangecontractswillbe johnsonjohnsonannualreportreclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthatperiod themaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcludinginter rateswapstheamountultimatelyrealizedinearningswilldifferasforeignexchangerateschangerealizedgainsand lossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtodesignatedderivativesforthefiscalyearsendeddecember andjanuary gainloss gainloss gainloss reclassifiedfrom recognizedin recognizedin accumulatedoci cashflowhedgesbyincomestatementcaption accumulatedoci intoincome incomeexpense dollarsinmillion salestocustomer costofproductssold researchanddevelopmentexpense interestincomeinterestexpensenet otherincomeexpensenet total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion foreignexchangecontract crosscurrencyinterestrateswap forthefiscalyearsendeddecemberandjanuaryagainofmillionandalossofmillion respectivelywasrecognizedinotherincomeexpensenetrelatingtoforeignexchangecontractsnotdesignatedas hedginginstrument fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbase measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelow thefairvalueofaderivativefinancialinstrumentieforwardexchangecontractcurrencyswapistheaggregationby currencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesandsubsequently convertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethatfairvaluesof thesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementormaturityorthat thechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyalsoholdsequityinvestmentsthatareclassifiedaslevelastheyaretradedinanactiveexchangemarket thecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequirerevisedvaluationsunder thisstandardthatarerecognizedatfairvalue thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilitie levelsignificantotherobservableinput levelsignificantunobservableinput johnsonjohnsonannualreport thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofdecemberandjanuary wereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset foreignexchangecontract crosscurrencyinterestrateswap total liability foreignexchangecontract crosscurrencyinterestrateswap total derivativesnotdesignatedashedginginstrument asset foreignexchangecontract swissfrancoption total liability foreignexchangecontract otherinvestment assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifie aslevel includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingdecemberandjanuary respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingdecemberandjanuary respectivelycrosscurrencyinterestrateswapsrelatedtooutstandingeurandgbpnotesmaturedinnovembertheswap weresettledatfairmarketvalueandreplacedwithnewswap currencyoptionrelatedtotheacquisitionofsynthesincwhichexpiredinjanuary classifiedasnoncurrentotherasset seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowing thecomponentsoflongtermdebtareasfollow effective effective dollarsinmillion rate rate debenturesdue notesdue debenturesdue monthliborfrndue monthliborfrndue notesdue notesdue debenturesdue debenturesdue notesduebeurobeuro zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue debenturesdue notesduemmgbpmmgbp notesdue debenturesdue notesdue debenturesdue debenturesdue notesdue lesscurrentportion weightedaverageeffectiverate translationrateatdecember translationrateatjanuary theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin fairvalueofthenoncurrentdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerprice andsignificantotherobservableinput thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbid providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementsarenotmaterial throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiarie thecompanyhasashelfregistrationwiththeussecuritiesandexchangecommissionthatenablesthecompanyto issuedebtsecuritiesandwarrantstopurchasedebtsecuritiesonatimelybasis johnsonjohnsonannualreport aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillion incometaxe theprovisionfortaxesonincomeconsistsof dollarsinmillion currentlypayable ustaxe internationaltaxe totalcurrentlypayable defer ustaxe internationaltaxe totaldeferre provisionfortaxesonincome acomparisonofincometaxexpenseattheusstatutoryrateofinandtothecompany effectivetaxrateisasfollow dollarsinmillion international earningsbeforetaxesonincome taxrate usstatutoryrate internationaloperationsexcludingireland irelandandpuertoricooperation researchandorphandrugtaxcredit usstateandlocal usmanufacturingdeduction ustaxoninternationalincome allother effectivetaxrate includesusexpensesnotfullytaxdeductibleprimarilyrelatedtolitigationexpense theincreaseintheeffectivetaxrateascomparedtowasduetolowertaxbenefitsontheimpairmentofin processresearchanddevelopmentintangibleassetsinlowtaxjurisdictionsincreasesintaxableincomeinhighertax jurisdictionsrelativetolowertaxjurisdictionsandtheexclusionofthebenefitoftheusresearchdevelopmentrd taxcreditandthecfclookthroughprovisionsfromthefiscalyearfinancialresultstherdtaxcreditandthecfc lookthroughprovisionswereenactedintolawinandwereretroactivetojanuarytheentirebenefitofthe rdtaxcreditandthecfclookthroughprovisionswillbereflectedinthefiscalyearfinancialresultstheincrease inthetaxrateascomparedtowasprimarilyduetocertainusexpenseswhicharenotfullytaxdeductible andhigherusstatetaxespartiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdictionsrelativetohighertax jurisdiction johnsonjohnsonannualreporttemporarydifferencesandcarryforwardsforandwereasfollow deferredtax deferredtax dollarsinmillion asset liability asset liability employeerelatedobligation stockbasedcompensation depreciation nondeductibleintangible internationalrdcapitalizedfortax reservesliabilitie incomereportedfortaxpurpose netoperatinglosscarryforwardinternational miscellaneousinternational miscellaneousus totaldeferredincometaxe thedifferencebetweenthenetdeferredtaxonincomeperthebalancesheetandthenetdeferredtaxaboveisincludedin taxesonincomeonthebalancesheetthecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenet lossesthecompanybelievesthatitismorelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincome sufficienttoutilizethesedeferredtaxasset thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefit dollarsinmillion beginningofyear increasesrelatedtocurrentyeartaxposition increasesrelatedtopriorperiodtaxposition decreasesrelatedtopriorperiodtaxposition settlement lapseofstatuteoflimitation endofyear theunrecognizedtaxbenefitsofbillionatdecemberifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudit inprogresswithanumberoftaxauthoritiestheusinternalrevenueserviceirshascompleteditsauditforthetax yearsthroughhowevertherearealimitednumberofissuesremainingopenforpriortaxyearsgoingbackto inothermajorjurisdictionswherethecompanyconductsbusinesstheyearsremainopengenerallybacktotheyear thecompanybelievesitispossiblethatauditsmaybecompletedbytaxauthoritiesinsomejurisdictionsoverthe nexttwelvemonthshoweverthecompanyisnotabletoprovideareasonablyreliableestimateofthetimingofanyother futuretaxpaymentsrelatingtouncertaintaxposition thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilitie interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestofmillionexpensemillionexpenseandmillionincomeinand respectivelythetotalamountofaccruedinterestwasmillionandmillioninandrespectively johnsonjohnsonannualreport employeerelatedobligation attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillion pensionbenefit postretirementbenefit postemploymentbenefit deferredcompensation totalemployeeobligation lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheet pensionsandotherbenefitplan thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependent manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsareprimarilybasedontheemployeescompensationduringthelastthreetofiveyearsbefore retirementandthenumberofyearsofserviceinternationalsubsidiarieshaveplansunderwhichfundsaredepositedwith trusteesannuitiesarepurchasedundergroupcontractsorreservesareprovide thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture thecompanyusesthedateofitsconsolidatedfinancialstatementsdecemberandjanuary respectivelyasthemeasurementdateforallusandinternationalretirementandotherbenefitplan netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecostcredit amortizationofnettransitionobligation recognizedactuariallosse curtailmentsandsettlement netperiodicbenefitcost amountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillion amortizationofnettransitionobligation amortizationofnetactuariallosse amortizationofpriorservicecost johnsonjohnsonannualreportunrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgain andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheprojectedbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridorareamortizedover theaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheremainingfutureserviceofplanparticipant atthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedovertheaverage remainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalue ofprojectedbenefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplan otherbenefitplan worldwidebenefitplans discountrate expectedlongtermrateofreturnonplanasset rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitie theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsource longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividual healthcareplan healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillion pointincrease pointdecrease healthcareplan totalinterestandservicecost postretirementbenefitobligation johnsonjohnsonannualreport thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplan otherbenefit retirementplan plan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuariallosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnlossonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear changesinplanassetsandbenefitobligationsrecognizedinother comprehensiveincome netperiodicbenefitcost netactuarialloss amortizationofnetactuariallossgain priorservicecost amortizationofpriorservicecostcredit effectofexchangerate totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome johnsonjohnsonannualreportthecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticea fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplan respectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberandjanuaryrespectively usplan internationalplans qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplansgross medicarerebate otherbenefitplansnet thefollowingtabledisplaystheprojectedfutureminimumcontributionstothecompanysusandinternationalunfunde retirementplanstheseamountsdonotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthe future dollarsinmillion projectedfuturecontribution unfundedusretirementplan unfundedinternationalretirementplan eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicle separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretiree durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplan permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefund johnsonjohnsonannualreport thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follow percentof target planasset allocation worldwideretirementplan equitysecuritie debtsecuritie totalplanasset determinationoffairvalueofplanasset theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquote marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilitie equityordebtpricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetassetvalue navprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsownedbythe fundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceinamarket thatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassifie aslevelleveldebtinstrumentsarepricedbasedonunobservableinput equitysecuritiescommonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy commingledfundstheinvestmentsarepublicinvestmentvehiclesvaluedusingthenavprovidedbythefund administratorthenavisbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthen dividedbythenumberofsharesoutstandingassetsinthelevelcategoryhaveaquotedmarketpriceinamarketthat isnotactive insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforprice johnsonjohnsonannualreport otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevelmostlimite partnershipsrepresentinvestmentsinprivateequityandsimilarfundsthatarevaluedbythegeneralpartnerstheseas wellasanyotherassetsvaluedusingunobservableinputsareclassifiedaslevel thefollowingtablesetsforththeretirementplanstrustinvestmentsmeasuredatfairvalueasofdecemberand january quotedprice significant inactive significant marketsfor observable unobservable identicalasset input input level level level totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund insurancecontract otherasset trustinvestmentsatfairvalue thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberandjanuaryrespectivelyandmillionofusshortterminvestmentfund levelatdecember thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatjanuary levelgainsandlosse thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearsende decemberandjanuary debt equity commingle insurance total dollarsinmillion instrument security fund contract asset level balancejanuary realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet balancejanuary realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet balancedecember johnsonjohnsonannualreport savingsplan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively capitalandtreasurystock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousand share balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans issuanceofcommonstockassociatedwiththeacquisitionofsynthesinc repurchaseofcommonstock balanceatdecember aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein includesrepurchaseofcommonstockassociatedwiththeacquisitionofsynthesinc accumulatedothercomprehensiveincome componentsofothercomprehensiveincomelossconsistofthefollowing gain total gain loss accumulate foreign loss employee currency benefit derivative comprehensive dollarsinmillion translation security plan hedge incomeloss january netchange january netchange january netchange december amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxesasitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome johnsonjohnsonannualreport internationalcurrencytranslation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyear orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulate othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingallbalancesheetassetsandliabilitie atcurrentexchangeratesexceptforthoselocatedinhighlyinflationaryeconomiesthetranslationofbalancesheet accountsforhighlyinflationaryeconomiesarereflectedintheoperatingresult arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillionand millioninandrespectively earningspershare thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsende decemberjanuaryandjanuary inmillionsexceptpershareamount basicnetearningspershareattributabletojohnsonjohnson averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshare acceleratedsharerepurchaseprogram adjustedaveragesharesoutstandingdilute dilutednetearningspershareattributabletojohnsonjohnson thedilutednetearningspersharecalculationincludesthedilutiveeffectofconvertibledebtthatisoffsetbytherelate reductionininterestexpenseofmillionaftertaxforyearsand dilutednetearningspershareexcludesmillionmillionandmillionsharesunderlyingstockoptionsfor andrespectivelyastheexercisepriceoftheseoptionswasgreaterthantheiraveragemarketvaluewhich wouldresultinanantidilutiveeffectondilutedearningspershare thedilutedearningspersharecalculationforthefiscalyearendeddecemberincludedthedilutiveeffectof millionsharesrelatedtotheacceleratedsharerepurchaseprogramassociatedwiththeacquisitionofsynthesinc seenotetotheconsolidatedfinancialstatementsforadditionaldetailsaincreasedecreaseinthevolume weightedaveragesharepricewouldimpactthisestimatebyapproximatelymillionshare rentalexpenseandleasecommitment rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatinglease wereapproximatelymillionmillionandmillioninandrespectively theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatdecemberare dollarsinmillion total commitmentsundercapitalleasesarenotsignificant johnsonjohnsonannualreport commonstockstockoptionplansandstockcompensationagreement atdecemberthecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontract underthecompanysstockoptionplanthelongtermincentiveplanthelongtermincentiveplan andthesciosincstockoptionplansthelongtermincentiveplanexpiredaprilalloptionsand restrictedsharesgrantedsubsequenttothatdatewereunderthelongtermincentiveplan thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementforshare basedcompensationcostswasmillionmillionandmillionforandrespectivelythe totalunrecognizedcompensationcostwasmillionmillionandmillionforand respectivelytheweightedaverageperiodforthiscosttoberecognizedwasyearsyearsandyearsfor andrespectivelysharebasedcompensationcostscapitalizedaspartofinventorywereinsignificant inallperiod stockoption stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrantunderthelongtermincentiveplanthecompanymayissueuptomillion sharesofcommonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentive plansubsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendof thecompanysettlesemployeestockoptionexerciseswithtreasurysharespreviouslytreasuryshareswerereplenishe throughouttheyearforthenumberofsharesusedtosettleemployeestockoptionexerciseshoweverpursuanttothe acceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofsynthesincthecompanyhasnotmade anypurchasesofcommonstockontheopenmarketduringthefiscalthirdandfourthquartersof thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableexpectedvolatilityrepresentsablendedrateofyeardaily historicalaveragevolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoneytradedjohnson johnsonoptionswithalifeofyearshistoricaldataisusedtodeterminetheexpectedlifeoftheoptiontheriskfreerate wasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythefair valuewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyear dividendyield johnsonjohnsonannualreportasummaryofoptionactivityundertheplanasofdecemberjanuaryandjanuaryandchanges duringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weight value outstanding average dollarsin sharesinthousand share exerciseprice millions sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatjanuary optionsgrante optionsexercised optionscanceledforfeite sharesatdecember thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatdecember sharesinthousand outstanding exercisable average average average exercise exercise exercisepricerange option life price option price averagecontractualliferemaininginyear stockoptionsexercisableatjanuaryandjanuarywereatanaveragepriceofandan averagelifeofyearsandatanaveragepriceofandanaveragelifeofyearsrespectively restrictedshareunitsandperformance shareunit thecompanygrantsrestrictedshareunitswithavestingperiodofthreeyearsthecompanyalsograntsperformance shareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockaftertheendofathreeyearperformance periodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistiedtotheachievementoverathree yearperiodofthreeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnsale adjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedatthe endofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgrante thecompanysettlesemployeestockissuanceswithtreasurysharespreviouslytreasuryshareswerereplenishe throughouttheyearforthenumberofsharesusedtosettleemployeestockissuanceshoweverpursuanttothe acceleratedstockrepurchaseagreementsinconnectionwiththeacquisitionofsynthesincthecompanyhasnotmade anypurchasesofcommonstockontheopenmarketduringthefiscalthirdandfourthquartersof johnsonjohnsonannualreport asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofdecemberis presentedbelow outstanding outstanding restricted performance sharesinthousand shareunit shareunit sharesatjanuary grant issue canceledforfeite sharesatjanuary grant issue canceledforfeite sharesatjanuary grant issue canceledforfeite sharesatdecember theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunit settledwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitswasincalculatedusingtheweighte averagefairmarketvalueforeachofthethreecomponentgoalsatthedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelnoperformanceshare unitswereissuedin segmentsofbusinessandgeographicarea salestocustomer dollarsinmillion consumer unitedstate international total pharmaceutical unitedstate international total medicaldevicesanddiagnostic unitedstate international total worldwidetotal johnsonjohnsonannualreportpretaxprofit identifiableasset dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic segmentstotal generalcorporate worldwidetotal salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinandthecompanydidnothaveacustomerthatrepresentedoftotalrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincome expenseincludesexpenseofbillionandbillionofcurrencyrelatedexpenserelatedtotheacquisitionofsynthesincin andrespectively generalcorporateincludescashandmarketablesecuritie includesmillionofnetlitigationexpensewhichincludesproductliabilitycomprisedofmillionandmillioninthe pharmaceuticalandmedicaldevicesanddiagnosticssegmentsrespectivelyincludesmillionofinprocessresearchand developmentexpensecomprisedofmillionandmillioninthepharmaceuticalandmedicaldevicesanddiagnostic segmentsrespectivelyincludesmillionofsynthesintegrationtransactioncostsinthemedicaldevicesanddiagnostic segmentincludesmillionofassetwritedownsandotheradjustmentscomprisedofmillionmillionand millioninthepharmaceuticalconsumerandmedicaldevicesanddiagnosticssegmentsrespectivelythemedicaldevicesand diagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhipprogram includesmillionofnetlitigationexpensewhichincludesproductliabilitycomprisedofmillionandmillionin thepharmaceuticalandmedicaldevicesanddiagnosticssegmentsrespectivelyincludesmillionofnetrestructuringexpense comprisedofmillionexpenseinthemedicaldevicesanddiagnosticssegmentandagainofmillioninthepharmaceutical segmentthemedicaldevicesanddiagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuy asrhipprogram includesmillionofnetlitigationgainwhichincludesproductliabilityexpensecomprisedofmillionexpenseinthe pharmaceuticalsegmentandagainofmillioninthemedicaldevicesanddiagnosticssegmentthemedicaldevicesand diagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhipprogram longlivedassetsincludepropertyplantandequipmentnetforandofand respectivelyandintangibleassetsandgoodwillnetforandofandrespectively johnsonjohnsonannualreport selectedquarterlyfinancialdataunaudite selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare second fourth second fourth datum quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomer consumer pharmaceutical meddevicesdiagnostic totalsale grossprofit earningsbeforeprovisionfortaxeson income netearningsattributabletojohnson johnson basicnetearningspershareattributable tojohnsonjohnson dilutednetearningspershare attributabletojohnsonjohnson thefirstquarterofincludesanaftertaxgainofmillionfromcurrencyandcostsassociatedwiththeacquisitionof synthesinc thesecondquarterofincludesaftertaxchargesofmillionforassetwritedownsmillionfromnetlitigation millionassociatedwiththeacquisitionofsynthesincandmillionfromimpairmentofinprocessresearchanddevelopment thethirdquarterofincludesaftertaxchargesofmillionassociatedwiththeacquisitionofsynthesincmillion fromimpairmentofinprocessresearchanddevelopmentmillionassociatedwithlitigationincludingproductliabilityand millionassociatedwiththedepuyasrhipprogram thefourthquarterofincludesaftertaxchargesofmillionfromnetlitigationincludingproductliabilitymillion associatedwiththeacquisitionofsynthesincmillionassociatedwiththedepuyasrhipprogramandmillionfrom impairmentofinprocessresearchanddevelopment thefirstquarterofincludesanaftertaxchargeofmillionfromnetlitigationincludingproductliabilityandthedepuy asrhipprogram thesecondquarterofincludesaftertaxchargesofmillionforrestructuringmillionfromlitigationincludingproduct liabilityandthedepuyasrhipprogrampartiallyoffsetbyamillionaftertaxgainassociatedwithanadjustmenttothevalue ofthecurrencyoptionrelatedtotheacquisitionofsynthesinc thethirdquarterofincludesamillionaftertaxchargeassociatedwithanadjustmenttothevalueofthecurrencyoption anddealcostsrelatedtotheacquisitionofsynthesinc thefourthquarterofincludesaftertaxchargesofmillionfromnetlitigationincludingproductliabilitymillionfor thecostassociatedwiththedepuyasrhipprogramandmillionassociatedwithanadjustmenttothevalueofthecurrency optionanddealcostsrelatedtotheacquisitionofsynthesinc businesscombinationsanddivestitures certainbusinesseswereacquiredformillionincashandstockandmillionofliabilitiesassumedduring theseacquisitionswereaccountedforbythepurchasemethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedsynthesincaglobaldeveloperandmanufactureroforthopaedicsdevicesguangzhou biosealbiotechcoltdadeveloperofbiologiccombinationsaddressingmoderatetoseverehemostasisangiotech pharmaceuticalsincintellectualpropertyandknowhowrelatedtothequillknotlesstissueclosuredevicecorlmmun incadeveloperofaphaseiitreatmentforchfcalibramedicalincdeveloperofauniquewearablethreedayinsulin patchforconvenientanddiscreetmealtimedosingforpeoplewithdiabeteswhotakemultipledailyinjectionsofinsulin spectrumvisionllcafullservicedistributorofcontactlensesservingrussiawithfacilitiesintheukraineand kazakhstanmarketingauthorizationstrademarksandpatentsextendingzyrtecrelatedmarketrightsinaustraliaand canada johnsonjohnsonannualreporttheexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionand hasbeenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofcorlmmunincand synthesinc theiprdrelatedtotheacquisitionofsynthesincofmillionisassociatedwithorthopaedicdevicesandtheiprd associatedwithcorlmmunofmillionisrelatedtoachftreatmenttheseiprdvalueswerecalculatedusingthe cashflowprojectionsdiscountedfortheriskinherentinsuchprojectssynthesinchadaprobabilityofsuccessfactorof discountedusingaratecorlmmunhadaprobabilityofsuccessfactorofdiscountedusingarate duringthefiscalsecondquarterthecompanycompletedtheacquisitionofsynthesincaglobaldeveloperand manufactureroforthopaedicsdevicesforapurchasepriceofbillionincashandstockthenetacquisitioncostof thetransactionisbillionbasedoncashonhandatclosingofbillion underthetermsoftheagreementeachshareofsynthesinccommonstockwasexchangedforchfincashand sharesofjohnsonjohnsoncommonstockbasedonthecalculatedexchangeratiotheexchangeratiowa calculatedonjuneandbasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommon stockonthatdatethetotalfairvalueofconsiderationtransferredwasbillionwhentheacquisitionwascomplete onjunebasedontherelevantexchangerateandclosingpriceofjohnsonjohnsoncommonstockonthat datethetotalfairvalueoftheconsiderationtransferredwasbillionjanssenpharmaceuticalacompanyorganize underthelawsofirelandandawhollyownedsubsidiaryofjohnsonjohnsonusedcashonhandtosatisfythecash portionofthemergerconsideration thestockportionofthemergerconsiderationconsistedofsharesofjohnsonjohnsoncommonstockpurchasedby janssenpharmaceuticalfromtwobankspursuanttotwoacceleratedsharerepurchaseasragreementsdate juneonjunejanssenpharmaceuticalpurchasedanaggregateofapproximatelymillionshares ofjohnsonjohnsoncommonstockataninitialpurchasepriceofbillionundertheasragreementswithallofthe sharesdeliveredtojanssenpharmaceuticalonjunefinalsettlementofthetransactionsundereachasr agreementisexpectedtooccurinthefirsthalfofandmayoccurearlierattheoptionofthetwobanksas applicableorlaterundercertaincircumstancesbasedonthetheoreticalsettlementoftheasragreementsanadditional millionshareswouldbeissuedtosettletheasragreementsasofdecember inadditionwhilethecompanybelievesthatthetransactionsundereachasragreementandaseriesofrelatedinternal transactionswereconsummatedinataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternal revenueservicecouldassertoneormorecontrarypositionstochallengethetransactionsfromataxperspectiveif challengedanamountuptothetotalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableus taxatapproximatelythestatutoryratetothecompanyplusinter thefollowingtablesummarizestheconsiderationtransferredtoacquiresynthesincvaluedontheacquisitiondateof june dollarsinmillion cashmultiplychfbysharesofsynthescommonstockoutstandingbytheexchangeratea commonstockmultiplybysharesofsynthescommonstockoutstandingbyjjstockpriceb totalfairvalueofconsiderationtransferre synthescommonstockoutstandingofmillionsharesasoftheacquisitiondateandchfusdexchangerateof b johnsonjohnsonclosingstockpriceonthenewyorkstockexchangeasofacquisitiondateofpershare thecompanyisstillfinalizingtheallocationofthepurchasepricetotheindividualassetsacquiredandliabilitiesassume theallocationofthepurchasepriceincludedinthecurrentperiodbalancesheetisbasedonthebestestimateof managementtoassistmanagementintheallocationthecompanyengagedvaluationspecialiststoprepareindependent appraisalscertainestimatedvaluessurroundinglitigationlosscontingenciesarenotyetfinalizedandaresubjectto changewewillfinalizetheamountsrecognizedasweobtaintheinformationnecessarytocompletetheanalysiswe expecttofinalizetheseamountsassoonaspossiblebutnolaterthanoneyearfromtheacquisitiondate johnsonjohnsonannualreport thefollowingtablepresentstheamountsrecognizedforassetsacquiredandliabilitiesassumedasoftheacquisitiondate aswellastheadjustmentsmadeuptodecember dollarsinmillions june december cashcashequivalent inventory accountsreceivablenet othercurrentasset propertyplantandequipment goodwill intangibleasset othernoncurrentasset totalassetsacquired currentliabilitie deferredtaxe othernoncurrentliabilitie totalliabilitiesassume netassetsacquired theadjustmentsmadesincethedateofacquisitionweretoaccountforchangestoinventorybasedontheresultsofthe physicalinventorycountsanddeferredtaxestoreflectthestatutorytaxratethatisbeingappliedtotheintangibleasset therevisionstothepurchasepriceallocationwerenotmaterialtothestatementsofconsolidatedearningsfortheprior fiscalquartersof theassetsacquiredarerecordedinthemedicaldevicesanddiagnosticssegmenttheacquisitionofsynthesinc resultedinbillionofgoodwillthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromtheacquisition ofsynthesincthegoodwillisnotexpectedtobedeductiblefortaxpurpose thepurchasepriceallocationtotheidentifiableintangibleassetsincludedinthejuneanddecember balancesheetswereasfollow dollarsinmillion june december intangibleassetswithdefinitelive customerrelationships patentsandtechnology totalamortizableintangible trademarkandtradename inprocessresearchanddevelopment totalintangibleasset theweightedaveragelifeforthebillionoftotalamortizableintangiblesisapproximatelyyear thetradenameassetvaluesweredeterminedtohaveanindefinitelifebasedonanumberoffactorsincludingtradename historythecompetitiveenvironmentmarketshareandfutureoperatingplanstheintangibleassetswithdefiniteliveswere assignedassetlivesrangingfromtoyear themajorityoftheintangibleassetvaluationrelatestocustomerrelationshipspatentsandtechnologyandtradename intangibleassetsinthecompanystraumacraniomaxillofacialspineandpowertoolsbusinesslinesadditionallyin processresearchanddevelopmentintangibleassetswerevaluedfortechnologyprogramsforunapprovedproduct thevalueoftheiprdwascalculatedusingcashflowprojectionsdiscountedfortheriskinherentinsuchprojectsthe discountrateappliedwa thecompanyisintheprocessofexecutingtheintegrationplanstocombinebusinessessalesorganizationssystem andlocationsasaresultofwhichthecompanyhasandwillcontinuetoincurintegrationcost johnsonjohnsonannualreporttheoperatingresultsofsyntheswerereportedinthecompanysfinancialstatementsbeginningonjunetotal salesandnetearningsforsynthesforthefiscalyearendeddecemberweremillionandmillion respectively thefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendeddecemberandjanuary asifsynthesinchadbeenacquiredasofjanuarytheproformaresultsincludetheeffectofdivestiture andcertainpurchaseaccountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseon theacquiredtangibleandintangibleassetshoweverproformaresultsdonotincludeanyanticipatedcostsavingsor othereffectsoftheintegrationofsynthesincaccordinglysuchamountsarenotnecessarilyindicativeoftheresultsifthe acquisitionhadoccurredonthedatesindicatedorwhichmayoccurinthefuture unauditedproforma consolidatedresult dollarsinmillionsexceptpershareamount netsale netearningsattributabletojohnsonjohnson dilutednetearningspershareattributabletojohnsonjohnson inthecompanyrecordedacquisitionrelatedcostsofmillionbeforetaxwhichwererecordedincostof productssoldandotherincomeexpense inconnectionwiththesynthesacquisitiondepuyorthopaedicsincagreedtodivestcertainrightsandassetsrelatedto itstraumabusinesstobiometincandcompletedtheinitialclosingforthistransactioninthefiscalsecondquarterof includingthosecountriesthatrepresentedthemajorityofsalesasofdecemberthetransactionhad closedworldwide certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforbythepurchasemethodandaccordinglyresultsofoperationshavebeenincludedinthe financialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedcrucellnvaglobalbiopharmaceuticalcompanyfocusedontheresearch developmentproductionandmarketingofvaccinesandantibodiesagainstinfectiousdiseaseworldwidetheoverthe counterbrandsofjbchemicalspharmaceuticalslimitedincludingrinzarussiasleadingmultisymptomcough andcoldbrandanddoktormomrussiasnumbertwosellingcoughbrandaswellasseveralotherbrandsfull ownershipofthejohnsonjohnsonmerckconsumerpharmaceuticalscojointventureintheusfrommercksharp dohmecorpandsterilmedincaleaderinthereprocessingandremanufacturingofmedicaldevicesintheus theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionofcrucellnv theiprdrelatedtotheacquisitionofcrucellnvofmillionisassociatedwithvaccinesandantibodiesthat preventandortreatinfectiousdiseasesthevalueoftheiprdwascalculatedusingcashflowprojectionsdiscounte fortheriskinherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwereusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwasduringthefiscalsecondquarterofthecompany recordedachargeofbillionfortheintangibleassetwritedownandbillionfortheimpairmentoftheinprocess researchanddevelopmentrelatedtothecrucellbusiness certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforbythepurchasemethodandaccordinglyresultsofoperationshavebeenincludedinthe financialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedacclarentincaprivatelyheldmedicaltechnologycompanydedicatedtodesigne developingandcommercializingdevicesthataddressconditionsaffectingtheearnoseandthroatentrespivertltda privatelyhelddrugdiscoverycompanyfocusedondevelopingsmallmoleculeinhaledtherapiesforthetreatmentof pulmonarydiseasesandmicrusendovascularllcaglobaldeveloperandmanufacturerofminimallyinvasivedevicesfor hemorrhagicandischemicstroke theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdassociatedwiththeacquisitionsofacclarentincrespivertltdand micrusendovascularllc johnsonjohnsonannualreport theiprdrelatedtotheacquisitionofacclarentincwasmillionandisassociatedwithnovelendoscopiccatheter baseddevicestomeettheneedsofentpatientsthevalueoftheiprdwascalculatedusingcashflowprojection discountedfortheriskinherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwereusedto reflectinherentclinicalandregulatoryriskthediscountrateappliedwas theiprdrelatedtotheacquisitionofrespivertltdwasmillionandisassociatedwithnarrowspectrumkinase inhibitorswithauniqueprofileofantiinflammatoryactivitiesastreatmentsformoderatetosevereasthmachronic obstructivepulmonarydiseasecopdandcysticfibrosiscfthevalueoftheiprdwascalculatedusingcashflow projectionsdiscountedfortheriskinherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwere usedtoreflectinherentclinicalandregulatoryriskthediscountrateappliedwa theiprdrelatedtotheacquisitionofmicrusendovascularllcwasmillionandisassociatedwithischemicand flowdivertertechnologiesthevalueoftheiprdwascalculatedusingcashflowprojectionsdiscountedfortherisk inherentinsuchprojectsprobabilityofsuccessfactorsrangingfromwereusedtoreflectinherentclinicaland regulatoryriskthediscountrateappliedwa withtheexceptionofthesynthesincacquisitionsupplementalproformainformationforandin accordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassetsisnot providedastheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsof operationscashflowsorfinancialposition duringthecompanydivestituresincludedbystolicnebivololiprightstoforestlaboratoriesincthetrauma businessofdepuyorthopaedicsinctobiometincthetherakosbusinesstoanaffiliateofgorescapitalpartnersiii lpthesaleofcertainconsumerbrandsandtherhogambusinessinthegainsonthedivestituresof businesseswerebillionduringthecompanydivestituresincludedtheanimalhealthbusinesstoelancoa divisionofelilillymonistatincanadatheusanditsterritoriesincludingpuertoricoassetsoftheortho dermatologicsdivisionintheustosubsidiariesofvaleantpharmaceuticalsinternationalincandthesurgical instrumentsbusinessofcodmanshurtleffincinthegainsonthedivestituresofbusinesseswerebillion duringthecompanydivestituresincludedthebreastcarebusinessofethiconendosurgeryincthegainson thesedivestitureswererecognizedinotherincomeexpensenet legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount ofthelosscanbereasonablyestimatedasofdecemberthecompanyhasdeterminedthattheliabilitie associatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthecompanyhasaccruedfor thesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther developmentsinaccordancewithascfortheseandotherlitigationandregulatorymatterscurrently disclosedforwhichalossisprobableorreasonablypossiblethecompanyisunabletodetermineanestimateofthe possiblelossorrangeoflossbeyondtheamountsalreadyaccruedthesematterscanbeaffectedbyvariousfactor includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscovery hasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiesthereare significantfactsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutioninanyreportingperiodofone ormoreofthesematterseitheraloneorintheaggregatemayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreportproductliability certainsubsidiariesofjohnsonjohnsonareinvolvedinnumerousproductliabilitycasesthedamagesclaimedare substantialandwhilethesesubsidiariesareconfidentoftheadequacyofthewarningsandinstructionsforusethat accompanytheproductsatissueitisnotfeasibletopredicttheultimateoutcomeoflitigationthecompanyha establishedproductliabilityaccrualsincompliancewithascbasedoncurrentlyavailableinformationwhichin somecasesmaybelimitedchangestotheaccrualsmayberequiredinthefutureasadditionalinformationbecome available multipleproductsofjohnsonjohnsonsubsidiariesaresubjecttoproductliabilityclaimsandlawsuitsinwhichclaimants seeksubstantialcompensatoryandwhereavailablepunitivedamagesincludinglevaquintheasrxlacetabular systemanddepuyasrhipresurfacingsystemthepinnacleacetabularcupsystemrisperdalpelvic meshesduragesicfentanylpatchesandtopamaxasofdecemberintheustherewere approximatelyplaintiffswithdirectclaimsinpendinglawsuitsregardinginjuriesallegedlyduetolevaquin withrespecttotheasrxlacetabularsystemanddepuyasrhipresurfacingsystemwithrespectto thepinnacleacetabularcupsystemwithrespecttorisperdalwithrespecttopelvicmeshe withrespecttoduragesicfentanylpatchesandwithrespecttotopamax inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonandthenumberofpendinglawsuitscontinuestoincreasecasesfiledin federalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfor thenortherndistrictofohiolitigationhasalsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunited kingdomcanadaandaustraliathecompanycontinuestoreceiveinformationwithrespecttopotentialcostsassociate withthisrecallduringthefiscalthirdandfourthquartersofthecompanyincreaseditsaccrualsforthedepuy asrhiprecallprogramandrelatedproductliabilityafterthecompanycompletedananalysisofnewinformation includingthenumberofexpectedclaimsrecentlyupdatedrevisionratesoftherecalledproductsandproductliability expensepercasechangestotheseaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavealsobeenmadeagainstdepuyandjohnsonjohnsonrelatingtodepuyspinnacle acetabularcupsystemthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompany continuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcasescasesfiledin federalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfor thenortherndistrictoftexasthecompanyhasestablishedaproductliabilityaccrualinanticipationofproductliability litigationassociatedwithdepuyspinnacleacetabularcupsystemchangestothisaccrualmayberequiredinthe futureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicon pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethenumberofpendingproduct liabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcost andtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwestvirginiainadditionaclassaction andseveralindividualpersonalinjurycaseshavebeencommencedincanadaandaustraliaseekingdamagesforallege injuryresultingfromethiconspelvicmeshdevicesthecompanyhasestablishedaproductliabilityaccrualinanticipation ofproductliabilitylitigationassociatedwithethiconspelvicmeshproductschangestothisaccrualmayberequiredin thefutureasadditionalinformationbecomesavailable thecompanybelievesthattheultimateresolutionofthesemattersbasedonhistoricalandreasonablylikelyfuturetrend isnotexpectedtohaveamaterialadverseeffectonthecompanysfinancialpositionannualresultsofoperationsand cashflowstheresolutioninanyinterimreportingperiodcouldhaveamaterialimpactonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreport intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessthemostsignificantofthesematter aredescribedbelow patentinfringement certainsubsidiariesofjohnsonjohnsonareinvolvedinlawsuitschallengingthecoverageandorvalidityofthepatent ontheirproductsalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensestothesechallengeswithrespect toallmaterialpatentstherecanbenoassuranceastotheoutcomeofthesemattersandalossinanyofthesecase couldpotentiallyadverselyaffecttheabilityofthesesubsidiariestoselltheirproductsorrequirethepaymentofpast damagesandfutureroyaltie medicaldevicesanddiagnostic inoctobertycohealthcaregrouplptycoandussurgicalcorporationfiledalawsuitagainstethiconendo surgeryinceesintheunitedstatesdistrictcourtforthedistrictofconnecticutallegingthatseveralfeaturesof eessharmonicscalpelinfringedfourtycopatentsinoctoberonmotionsforsummaryjudgmentpriortothe initialtrialanumberofclaimswerefoundinvalidandanumberwerefoundinfringedhowevernoclaimwasfoundboth validandinfringedtrialcommencedindecemberandthecourtdismissedthecasewithoutprejudiceonground thattycodidnotownthepatentsinsuitthedismissalwithoutprejudicewasaffirmedonappealinjanuarytyco filedanothercomplaintintheunitedstatesdistrictcourtforthedistrictofconnecticutassertinginfringementofthreeof thefourpatentsfromthepreviouslawsuitandaddingnewproductstycoisseekingmonetarydamagesandinjunctive reliefthecasewastriedinjulyandthepartiesareawaitingadecisionfromthecourt inoctoberbrucesaffransaffranfiledapatentinfringementlawsuitagainstjohnsonjohnsonandcordis corporationcordisintheunitedstatesdistrictcourtfortheeasterndistrictoftexasalleginginfringementonus patentnoinjanuaryajuryreturnedaverdictfindingthatcordisssalesofitscypherstentwillfully infringedthepatentthejuryawardedsaffranmillioninmarchthecourtenteredjudgmentagainst cordisintheamountofmillionrepresentingthejuryverdictplusmillioninprejudgmentinterestcordishas appealedthejudgmentoralargumentwasheardindecemberandadecisionfromthecourtofappealsis pendingbecausethecompanybelievesthatthepotentialforanunfavorableoutcomeisnotprobableithasnot establishedanaccrualwithrespecttothecase innovemberrochediagnosticsoperationsincetalrochefiledapatentinfringementlawsuitagainstlifescan inclifescanintheunitedstatesdistrictcourtforthedistrictofdelawareaccusinglifescansentireonetouchline ofbloodglucosemonitoringsystemsofinfringementoftwopatentsrelatedtotheuseofmicroelectrodesensorsin septemberlifescanobtainedafavorablerulingonclaimconstructionthatprecludedafindingofinfringementthe courtenteredjudgmentagainstrocheinjulyandrocheappealedthecourtofappealsreversedthedistrict courtsrulingonclaimconstructionandremandedthecasetothedistrictcourtfornewfindingsontheissuethepartie areawaitingarulingonclaimconstructionrocheisseekingmonetarydamagesandinjunctiverelief injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvcintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcs manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringetheirus patentnothechangpatentrembrandtisseekingmonetaryreliefthecasewastransferredtotheunite statesdistrictcourtforthemiddledistrictoffloridainmaythejuryreturnedaverdictholdingthatneitherofthe accusedlensesinfringethepatentrembrandthasfiledanappealwiththeunitedstatescourtofappealsforthe federalcircuit innovemberhowmedicaosteonicscorphowmedicaandstrykerirelandltdstrykerfiledapatent infringementlawsuitagainstdepuyorthopaedicsincdepuyintheunitedstatesdistrictcourtforthedistrictofnew jerseyalleginginfringementbydepuyspinnacleacetabularcupsystemandduralocacetabularcupsystemof apatentrelatingtoaduallockingmechanismfeatureinanacetabularcupsystemhowmedicaandstrykerareseeke monetarydamagesandinjunctivereliefdepuyfileditsanswerinfebruaryandfiledacounterclaimassertingthat strykerstridentacetabularhipsysteminfringesdepuysuspatentnodepuyisseekingdamagesand injunctiverelieffromhowmedicaandstryker johnsonjohnsonannualreportinmaymedtronicminimedincmedtronicpuertoricooperationscoandminimeddistributioncorpcollectively medtronicminimedfiledapatentinfringementlawsuitagainstanimascorporationintheunitedstatesdistrictcourtfor thecentraldistrictofcaliforniaallegingthatanimasonetouchpingglucosemanagementsysteminfringesnineof theirpatentsmedtronicminimedisseekingmonetarydamagesandinjunctiverelief injunedepuyorthopaedicsincdepuyfiledadeclaratoryjudgmentactionagainstorthopaedichospitalohin theunitedstatesdistrictcourtforthenortherndistrictofindianaseekingadeclarationofthepartiesrightsand obligationsunderapatentrightsandlicenseagreementbetweenthepartiesrelatedtodevelopmentofapolyethylene materialohhasclaimedthatdepuyowesroyaltiesonproductsmadewithantioxidantpolyethylenedepuydisputesthat itowessuchroyaltiestoohandisthusseekingadeclarationfromthecourtondisputedcontractualprovisionsafter depuyfiledthedeclaratoryjudgmentactionohfiledaseparatesuitonthesamesubjectmatterintheunitedstate districtcourtforthecentraldistrictofcaliforniaandmovedforconsolidationwiththecaliforniacase pharmaceutical inmayabbottbiotechnologyltdabbottfiledapatentinfringementlawsuitagainstcentocorinccentocor nowjanssenbiotechincjbiintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthat simponiinfringesabbottsuspatentnosandthesalfeldpatentsabbottisseeke monetarydamagesandinjunctivereliefinaprilthepartiesparticipatedinanarbitrationontheissueofjbis defensethatabbottisequitablyestoppedfromassertingthepatentsinmaythearbitratorrejectedjbisdefense thecasehasbeenreinstatedinthedistrictcourtandfactdiscoveryisongoe inaugustabbottgmbhcoabbottgmbhandabbottbioresearchcenterfiledapatentinfringementlawsuit againstcentocornowjbiintheunitedstatesdistrictcourtforthedistrictofmassachusettsallegingthatstelara infringestwounitedstatespatentsassignedtoabbottgmbhjbifiledacomplaintintheunitedstatesdistrictcourtfor thedistrictofcolumbiaforadeclaratoryjudgmentofnoninfringementandinvalidityoftheabbottgmbhpatentsaswell asacomplaintforreviewofapatentinterferencedecisionthatgrantedpriorityofinventionononeofthetwoasserted patentstoabbottgmbhthecaseshavebeentransferredfromthedistrictofcolumbiatothedistrictofmassachusetts trialwasheldinseptemberwithajuryverdictinfavorofcentocorinvalidatingabbottspatentclaimsposttrial briefinghasbeencompletedandthepartiesareawaitingadecisionalsoinaugustabbottgmbhandabbott laboratorieslimitedbroughtapatentinfringementlawsuitinthefederalcourtofcanadaallegingthatstelara infringesabbottgmbhscanadianpatentatrialisscheduledfordecemberinthecanadiancaseinadditionto theusandcanadianlitigationsinaugustabbottfiledpatentinfringementlawsuitsinthenetherland switzerlandandgermanyineachoftheabovecasesabbottisseekingmonetarydamagesandinjunctiverelief litigationagainstfilersofabbreviatednewdrugapplicationsanda thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthatfiledabbreviatednewdrugapplication andasseekingtomarketgenericformsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpiration oftheapplicablepatentscoveringthoseproductstheseandastypicallyincludeallegationsofnoninfringement invalidityandunenforceabilityofthesepatentsintheeventthesubsidiariesarenotsuccessfulintheseactionsorthe statutorymonthstaysexpirebeforetheunitedstatesdistrictcourtrulingsareobtainedthethirdpartycompanie involvedwillhavetheabilityuponapprovaloftheunitedstatesfoodanddrugadministrationfdatointroducegeneric versionsoftheproductsatissueresultinginverysubstantialmarketshareandrevenuelossesforthoseproduct concerta anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofconcertain septemberasettlementagreementwasenteredintowithkremersurbanllcandkudcoirelandltd collectivelykudcopursuanttowhichkudcowasgrantedalicenseunderthepatentinsuittomarketitsgeneric versionofconcertastartingonjulyifandwhenkudcoobtainsfdaapproval innovemberalzacorporationalzaandorthomcneiljanssenpharmaceuticalsincomjpinowjanssen pharmaceuticalsincjpifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof delawareagainstimpaxlaboratoriesincimpaxtevapharmaceuticalsusaincandtevapharmaceuticalindustries ltdcollectivelytevainresponsetoimpaxandtevasfilingofamajoramendmenttoitsandaseekingapprovalto marketagenericversionofconcertabeforetheexpirationofalzaandjpispatentrelatingtoconcertaimpax johnsonjohnsonannualreport andtevafiledcounterclaimsallegingnoninfringementandinvalidityinmayalzaandjpifiledasecondlawsuit againsttevainresponsetotevasfilingofasecondmajoramendmenttoitsandaseekingapprovaltomarketadditional dosagestrengthsofitsgenericconcertaproductbeforetheexpirationofalzaandjpispatentrelatingto concertaineachoftheabovecasesalzaandjpisoughtanorderenjoiningthedefendantsfrommarketingit genericversionofconcertapriortotheexpirationofalzaandjpisconcertapatentinseptembera settlementagreementwasenteredintowithimpaxandtevapursuanttowhichthosepartiesweregrantedalicenseunder thepatentinsuittomarkettheirgenericversionofconcertastartingjulyorearlierundercertain circumstancesifandwhentheyobtainfdaapproval orthotricyclenlo anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsoforthotricyclen loinfebruaryjpiandwatsonlaboratoriesincandwatsonpharmaceuticalsinccollectivelywatsonentere intoasettlementagreementpursuanttothesettlementagreementthepartiesenteredintoasupplyagreementwhereby jpiwillsupplytowatsonacombinationaloralcontraceptivecontainingcertainspecifiedcompoundsfromdecember orearlierundercertaincircumstancesthroughtheexpirationofthepatentondecemberinaddition intheeventwatsondoesnotwishtoexerciseitsrightsunderthesupplyagreementjpihasgrantedwatsonalicenseto marketwatsonsandaproductfromdecemberorearlierundercertaincircumstancesthroughdecember injanuaryomjpinowjpifiledapatentinfringementlawsuitagainstlupinltdandlupinpharmaceuticalsinc collectivelylupinintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetolupinsandaseeke approvaltomarketagenericversionoforthotricyclenlopriortotheexpirationofjpispatentrelatingto orthotricyclenlotheotclopatentlupinfiledacounterclaimalleginginvalidityofthepatenttrial concludedinjuneandinseptemberthecourtissuedadecisioninfavorofjpiinparticularthecourt orderedthattheeffectivedateoftheapprovaloflupinsandawhichhadpreviouslybeenapprovedbenotearlierthan theexpirationoftheotclopatentlupinhasappealedthedecisiontothecourtofappealsforthefederalcircuitoral argumentwasheardinfebruaryandthecourtsdecisionispending innovemberomjpinowjpifiledapatentinfringementlawsuitagainstmylanincandmylanpharmaceuticalsinc collectivelymylanandfamycareltdfamycareintheunitedstatesdistrictcourtforthedistrictofnewjerseyin responsetofamycaresandaseekingapprovaltomarketagenericversionoforthotricyclenlopriortothe expirationoftheotclopatentmylanandfamycarefiledcounterclaimsalleginginvalidityofthepatentinnovember jpiandmylanenteredintoasettlementagreementpursuanttowhichmylanwasgrantedalicenseunderthe otclopatenttomarketitsgenericversionoforthotricyclenlostartingdecemberorearlierunder certaincircumstancesifandwhentheyobtainfdaapproval inoctoberjpifiledapatentinfringementlawsuitagainstsunpharmaglobalfzeandsunpharmaceutical industriescollectivelysunintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetosunsanda seekingapprovaltomarketagenericversionoforthotricyclenlopriortotheexpirationoftheotclopatent inmayjpifiledapatentinfringementlawsuitagainsthauptpharmaincranbaxylaboratorieslimitedand ranbaxyinccollectivelyhauptintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetohaupt andaseekingapprovaltomarketagenericversionoforthotricyclenlopriortotheexpirationoftheotclo patentindecemberjpiandhauptenteredintoasettlementagreementpursuanttowhichhauptwasgranteda licenseundertheotclopatenttomarketitsgenericversionoforthotricyclenlostartingdecember orearlierundercertaincircumstancesifandwhentheyobtainfdaapproval inaugustjpifiledapatentinfringementlawsuitagainstglenmarkgenericsltdandglenmarkgenericsincusa collectivelyglenmarkintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetoglenmarksanda seekingapprovaltomarketagenericversionoforthotricyclenlopriortotheexpirationoftheotclopatent innovemberasettlementagreementwasenteredintowithglenmarkpursuanttowhichglenmarkwasgranteda licenseundertheotclopatenttomarketitsgenericversionoforthotricyclenlostartingdecember orearlierundercertaincircumstancesifandwhentheyobtainfdaapproval ineachoftheabovecasesjpisoughtorisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsoforthotricylcenlobeforetheexpirationoftheotclopatent johnsonjohnsonannualreportprezista anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofprezistain novembertibotecincnowtibotecllcandtibotecpharmaceuticalsnowjanssenrdirelandcollectively tibotecfiledapatentinfringementlawsuitagainstlupinltdlupinpharmaceuticalsinccollectivelylupinmylaninc andmylanpharmaceuticalsinccollectivelymylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyin responsetolupinsandmylansrespectiveandasseekingapprovaltomarketgenericversionsoftibotecsprezista productbeforetheexpirationoftibotecspatentrelatingtoprezistalupinandmylaneachfiledcounterclaim allegingnoninfringementandinvalidityinjulytibotecfiledanotherpatentinfringementlawsuitagainstlupininthe unitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetolupinssupplementtoitsandatoaddnew dosagestrengthsforitsproposedproductinaugusttibotecandgdsearlecompanygdsearlefileda patentinfringementlawsuitagainstlupinandmylaninresponsetotheirnoticelettersadvisingthattheirandasare seekingapprovaltomarketgenericversionsoftibotecsprezistaproductbeforetheexpirationoftwopatentsrelating toprezistathattibotecexclusivelylicensesfromgdsearle inmarchtibotecandgdsearlefiledapatentinfringementlawsuitagainsttevapharmaceuticalsusaincand tevapharmaceuticalsltdcollectivelytevaintheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponse totevasandaseekingapprovaltomarketagenericversionofprezistabeforetheexpirationofcertainpatent relatingtoprezistathattiboteceitherownsorexclusivelylicensesfromgdsearle inmarchtibotecfiledapatentinfringementlawsuitagainstheterodrugsltdunitiiiandheterousainc collectivelyheterointheunitedstatesdistrictcourtforthedistrictofnewjerseyinresponsetoheterosanda seekingapprovaltomarketagenericversionofprezistabeforetheexpirationofcertainpatentsrelatingto prezistathattibotecexclusivelylicensesfromgdsearleinjulyuponagreementbythepartiesthecourt enteredastayofthelawsuitpendingafinaldecisioninthelawsuitagainsttevawithrespecttothevalidityandor enforceabilityofthepatentsthattiboteclicensesfromgdsearlewithheteroagreeingtobeboundbysuchfinal decision inseptemberthecourtconsolidatedtheabovelawsuitsaswellaslawsuitsbroughtbytheunitedstate governmentagainsteachofthedefendantsforinfringementofaunitedstatesgovernmentownedpatentrelatingto prezistaforpurposesofpretrialdiscoveryandtrialwiththeprovisothatafterdiscoveryiscompletedanypartycan movetohavethecasesdeconsolidatedfortrial inmayandjunejanssenproductslpandjanssenrdirelandcollectivelyjanssenandgdsearlefileda patentinfringementlawsuitagainstlupintevaandmylanintheunitedstatesdistrictcourtforthedistrictofnewjersey alleginginfringementofnewlyissuedunitedstatesreissuepatentnorewhichjanssenexclusivelylicense fromgdsearleinaugustjanssenandgdsearlefiledapatentinfringementlawsuitagainstlupintevaand mylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyalleginginfringementofnewlyissuedunitedstate reissuepatentnorewhichjanssenexclusivelylicensesfromgdsearlethesecaseshavebeenconsolidate withtheabovelawsuitsinoctoberjanssenfiledamotiontofileasupplementalcomplaintagainstlupintevaand mylanintheunitedstatesdistrictcourtforthedistrictofnewjerseyalleginginfringementofunitedstatespatentno mylanonlylupinandtevaonlyandlupinandtevaonlyinjanuarythe courtpermittedthesethreeadditionalpatentstobeaddedtotheconsolidatedaction ineachoftheabovelawsuitstibotecandjanssenareseekinganorderenjoiningthedefendantsfrommarketingtheir genericversionsofprezistabeforetheexpirationoftherelevantpatent otherintellectualpropertymatter inseptembercentocororthobiotechproductslpnowjanssenproductslpjplpintervenedinan inventorshiplawsuitfiledbytheuniversityofkansascenterforresearchinckucragainsttheunitedstatesof americausaintheunitedstatesdistrictcourtforthedistrictofkansaskucrallegesthattwokucrscientist shouldbeaddedasinventorsontwousaownedpatentsrelatingtovelcadetheusalicensedthepatentsand theirforeigncounterpartstomillenniumpharmaceuticalsincmpiwhointurnsublicensedthepatentsandtheirforeign counterpartstojplpforcommercialmarketingoutsidetheunitedstatesinjulythepartiesreachedasettlement agreementtoresolvethedisputesinthiscaseandsubmittedtheinventorshipissuetoarbitrationtheoutcomeofwhich woulddeterminewhetherprespecifiedpaymentswouldbemadetokucrbutwillnotaffectjplpsrighttomarket velcadethearbitrationtookplaceindecemberandadecisioninfavorofkucrwasissuedinmarcha aresultjplpwillberequiredtomaketheaforementionedprespecifiedpaymentstokucr johnsonjohnsonannualreport indecemberthestateofisraelfiledalawsuitinthedistrictcourtintelavivjaffaagainstomrix biopharmaceuticalsincandvariousaffiliatesomrixinthelawsuitthestateclaimsthatanemployeeofagovernment ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe wasagovernmentemployeethestateclaimsthathehadnorighttotransferanyintellectualpropertytoomrixbecauseit belongstothestatethestateisseekingdamagesplusroyaltiesonquixilandevicelproductsoralternatively transferofthepatentstothestate injanuarygenentechincgenentechinitiatedanarbitrationagainstucbcelltechcelltechseekingdamagesfor allegedlycooperatingwithcentocorincnowjanssenbiotechincjbitoimproperlyterminateaprioragreementin whichjbiwassublicensedundergenentechscabillypatentstosellremicadejbihasanindemnityagreementwith celltechandcelltechassertedthatjbiwouldbeliableforanydamagescelltechmayberequiredtopaygenentechinthat arbitrationfollowinganarbitrationhearinginjunethearbitratorsissuedadecisionfindingnoliabilityforcelltech andthereforejbiisnotliableforanypotentialindemnityclaimjbihasmovedtorecoveritsattorneysfeescostsand expense inmarchnoramcoincnoramcomovedtointerveneinthreepatentinfringementlawsuitsfiledintheunite statesdistrictcourtforthesoutherndistrictofnewyorksdnybypurduepharmalpandotherspurdueagainst noramcooxycodonecustomersimpaxlaboratoriesincimpaxtevapharmaceuticalsusainctevaandamneal pharmaceuticalsllcamnealinfebruarynoramcoappearedonbehalfofnoramcocustomerswatson laboratoriesincfloridaandandrxlabsllccollectivelywatsonandrxinasimilarlawsuitfiledbypurdueinthe sdnythelawsuitsareinresponsetothedefendantsrespectiveandasseekingapprovaltomarketgenericextende releaseoxycodoneproductsbeforetheexpirationofcertainpurduepatentsthreeoftheassertedpatentsrelateto oxycodoneandprocessesformakingoxycodoneandnoramcohasagreedtodefendthelawsuitsonbehalfofimpax tevaamnealandwatsonandrxalthoughnoramcodidnotparticipateinnovemberatrialinalawsuitbroughtby purdueagainstanothernoramcocustomeractaviselizabethllcactavistookplacebecausetheactiveingredientat issueintheactavislawsuitisthesameastheactiveingredientatissueintheabovelawsuitsthedistrictcourtsdecision intheactaviscasemayaffectthoselawsuitsadecisionfromthedistrictcourtintheactaviscaseispende inaugustdrjamesmswansonswansonfiledalawsuitagainstalzacorporationalzainthenorthern districtofcaliforniaseekingtobeaddedasaninventorontwoalzaownedpatentsrelatingto concertaalternativelydrswansonhasallegedthatthepatentsinsuitareinvalidandorunenforceableasaresult ofalzasallegedomissionofdrswansonasanamedinventoronthepatentsdrswansonisseekingdamagesandan awardofunjustenrichmentalzafiledamotiontodismissswansonsclaimsandoralargumentisscheduledforfebruary governmentproceedings likeothercompaniesinthepharmaceuticalandmedicaldevicesanddiagnosticsindustriesjohnsonjohnsonand certainofitssubsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunite statesandothercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemost significantlitigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethat criminalchargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsor litigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompaniesaredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct becauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesalepriceawpforthedrug atissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsmanyofthesecase bothfederalactionsandstateactionsremovedtofederalcourtwereconsolidatedforpretrialpurposesinamultidistrict litigationmdlintheunitedstatesdistrictcourtforthedistrictofmassachusetts theplaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchase ofthedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpinjuneafteratrialonthemeritsthemdlcourtdismissedtheclaimsoftwooftheplaintiffclasse againstthejjawpdefendantsinmarchthecourtdismissedtheclaimsofthethirdclassagainstthejjawp defendantswithoutprejudice johnsonjohnsonannualreportawpcasesbroughtbyvariousattorneysgeneralhaveproceededtotrialagainstothermanufacturersseveralstate casesagainstcertainsubsidiariesofjohnsonjohnsonhavebeensettledincludingkentuckywhichhadbeensetfor trialinjanuaryandkansaswhichhadbeensetfortrialinmarchlouisianaandmississippiaresetfortrialin octoberillinoisissetfortrialinmayandalaskaissetfortrialinjulyotherstatecasesarelikelytobe setfortrialinduecourseinadditionanawpcaseagainstthejjawpdefendantsbroughtbythecommonwealthof pennsylvaniawastriedincommonwealthcourtinoctoberandnovemberthecourtfoundinthe commonwealthsfavorwithregardtocertainofitsclaimsunderthepennsylvaniaunfairtradepracticesandconsumer protectionlawutplenteredaninjunctionandawardedmillioninrestitutionandmillionincivilpenaltiesthe courtfoundinthejjawpdefendantsfavoronthecommonwealthsclaimsofunjustenrichmentmisrepresentation fraudcivilconspiracyandoncertainofthecommonwealthsclaimsundertheutplthejjawpdefendantshave appealedthecommonwealthcourtsutplrulingtothepennsylvaniasupremecourtthecompanybelievesthatthejj awpdefendantshavestrongargumentssupportingtheirappealbecausethecompanybelievesthatthepotentialforan unfavorableoutcomeisnotprobableithasnotestablishedanaccrualwithrespecttotheverdict risperdal injanuaryjanssenpharmaceuticaincjanssenpharmaceuticanowjanssenpharmaceuticalsincjpireceive asubpoenafromtheofficeoftheinspectorgeneraloftheunitedstatesofficeofpersonnelmanagementseeking documentsconcerningsalesandmarketingofanyandallpaymentstophysiciansinconnectionwithsalesandmarkete ofandclinicaltrialsforrisperdalfromtodocumentssubsequenttohavealsobeenrequestedby thedepartmentofjusticeanadditionalsubpoenaseekinginformationaboutmarketingofandadversereactionsto risperdalwasreceivedfromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniain novembernumeroussubpoenasseekingtestimonyfromvariouswitnessesbeforeagrandjurywerealsoreceive jpicooperatedinrespondingtotheserequestsfordocumentsandwitnessestheunitedstatesdepartmentofjustice andtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathegovernmentarecontinuingtoactively pursuebothcriminalandcivilactionsinfebruarythegovernmentservedcivilinvestigativedemandsseeke additionalinformationrelatingtosalesandmarketingofrisperdalandsalesandmarketingofinvegathefocusof thesemattersistheallegedpromotionofrisperdalandinvegaforofflabelusesthegovernmenthasnotifiedjpi thattherearealsopendingquitamactionsallegingofflabelpromotionofrisperdalthegovernmentinformedjpi thatitwillinterveneinthesequitamactionsandfileasupersedingcomplaint indiscussionstoresolvecriminalpenaltiesunderthefooddrugandcosmeticactrelatedtothepromotionof risperdalresultedinanagreementinprinciplewiththeunitedstatesattorneysofficefortheeasterndistrictof pennsylvaniaonkeyissuesrelevanttoadispositionofcriminalchargespursuanttoasinglemisdemeanorviolationofthe fooddrugandcosmeticactbutcertainissuesremainopenbeforeasettlementcanbefinalizedduringthe companyaccruedamountstocoverthefinancialcomponentoftheproposedcriminalsettlement inthecompanyalsoreachedanagreementinprinciplewiththeunitedstatesdepartmentofjusticetosettlethree pendingcivilfalseclaimsactmattersthatarependingintheeasterndistrictofpennsylvaniaconcerningsalesand marketingofrisperdalandinvegathenortherndistrictofcaliforniaregardingthesalesandmarketingof natrecordiscussedseparatelybelowandthedistrictofmassachusettsallegingthatthedefendantsprovide theomnicareincomnicarelongtermcarepharmacywithrebatesandotherpaymentsregardingrisperdaland otherproductsdiscussedseparatelybelowassumingtheseagreementsarefinalizedtheywillresolvethefederal governmentsclaimsunderthefederalfalseclaimsactresolveallpendingstateandfederalgovernmentlitigation regardingomnicareandnatrecorandsettletherisperdalmedicaidrelatedclaimsforthosestatesthatoptinto thesettlementwiththetentativesettlementagreementsdescribedaboveissuesremainopenthatmustberesolved beforethesettlementscanbefinalize thecompanyhasaccruedamountsincludinganadditionalaccrualmadeinthesecondquarteroftocoverthese tentativesettlementagreementshoweverthesettlementswillnotresolveallpendingstatelitigationmattersregarding risperdalandsomestatesmayelecttooptoutofthesettlementstotheextentanystatehasaclaimandhasorwill electtooptoutofthesesettlementsthecompanyhasaccruedanamountequaltowhatthatstatewouldreceiveifitwa participatinginthesettlementsamongotherstatesarkansaslouisianaandsouthcarolinaarenotexpectedto participateinthesettlementsasdiscussedbelowbecausethecompanybelievestherearestrongargumentsonappeal inthosecasesthecompanyhasonlyaccruedanamountequaltowhatthesestateswouldreceiveiftheyparticipatedin thesettlement inadditiontheattorneysgeneralofmultiplestatesincludingalaskaarkansaslouisianamassachusettsmississippi montananewmexicosouthcarolinaandutahhavependingactionsagainstjanssenpharmaceuticanowjpiseeke johnsonjohnsonannualreport oneormoreofthefollowingremediesreimbursementofmedicaidorotherpublicfundsforrisperdalprescription writtenforofflabelusecompensationfortreatingtheircitizensforallegedadversereactionstorisperdalcivilfine orpenaltiesdamagesforoverpaymentsbythestateandothersviolationsofstateconsumerfraudstatutespunitive damagesorotherreliefrelatingtoallegedunfairbusinesspracticescertainoftheseactionsalsoseekinjunctiverelief relatingtothepromotionofrisperdalinjanuaryjpisettledalawsuitfiledbytheattorneygeneraloftexasin aprilinthelawsuitbroughtbytheattorneygeneralofarkansasthejuryfoundagainstbothjpiandjohnson johnsonandthecourtimposedpenaltiesintheamountofapproximatelybillionjpiandjohnsonjohnsonhave filedanappealandbelievethattheyhavestrongargumentssupportingtheappealinjanuarythesamecourt awardedattorneyfeesofapproximatelymillionthisjudgmentwillalsobeappeale theattorneygeneralofwestvirginiacommencedsuitinagainstjanssenpharmaceuticanowjpibasedon claimsofallegedconsumerfraudastoduragesicaswellasrisperdaljpiwasfoundliableanddamageswere assessedatmillionjpifiledanappealandinnovemberthewestvirginiasupremecourtreversedthetrial courtsdecisionindecembertheattorneygeneralofwestvirginiadismissedthecaseasitrelatedto risperdalwithoutanypaymentthereafterjpisettledthecaseinsofarasitrelatedtoduragesic intheattorneygeneraloflouisianafiledamulticountcomplaintagainstjanssenpharmaceuticanowjpi johnsonjohnsonwaslateraddedasadefendantthecasewastriedinoctobertheissuetriedtothejurywa whetherjohnsonjohnsonorjpihadviolatedthestatesmedicaidfraudacttheactthroughmisrepresentations allegedlymadeinthemailingofanovemberdearhealthcareprofessionalletterregardingrisperdalthejury returnedaverdictthatjpiandjohnsonjohnsonhadviolatedtheactandawardedmillionindamagesthetrial judgesubsequentlyawardedtheattorneygeneralcounselfeesandexpensesintheamountofmillioninaugust aninterlocutoryappellatecourtaffirmedthejudgmentinjanuarythelouisianasupremecourtaccepte johnsonjohnsonandjpisrequestforappealoralargumentontheappealhasbeensetformarch intheofficeofgeneralcounselofthecommonwealthofpennsylvaniafiledalawsuitagainstjanssen pharmaceuticanowjpionamulticountcomplaintrelatedtojanssenpharmaceuticassaleofrisperdaltothe commonwealthsmedicaidprogramthetrialoccurredinjunethetrialjudgedismissedthecaseafterthecloseof theplaintiffsevidencethecommonwealthfiledanappealinaprilandinjulythepennsylvaniaappeal courtupheldthedismissalofthecommonwealthscase intheattorneygeneralofsouthcarolinafiledalawsuitagainstjohnsonjohnsonandjanssenpharmaceutica nowjpionseveralcountsinmarchthematterwastriedonliabilityonlyatwhichtimethelawsuitwaslimitedto claimsofviolationofthesouthcarolinaunfairtradepracticeactincludingamongothersquestionsofwhether johnsonjohnsonorjpiengagedinunfairordeceptiveactsorpracticesintheconductofanytradeorcommerceby distributingthenovemberdearhealthcareprofessionalletterregardingrisperdalorintheiruseofthe productsfdaapprovedlabelthejuryfoundinfavorofjohnsonjohnsonandagainstjpiinjunethecourt awardedcivilpenaltiesofapproximatelymillionjpihasappealedthisjudgmentandthecompanybelievesitha strongargumentssupportingtheappealoralargumentontheappealhasbeensetbeforethesouthcarolinasupreme courtformarch theattorneysgeneralofapproximatelyotherstatesandthedistrictofcolumbiaindicatedaninterestinpursue similarlitigationagainstjpiandobtainedatollingagreementstayingtherunningofthestatuteoflimitationswhilethey pursuedaninvestigationofjpiregardingpotentialconsumerfraudactionsinconnectionwiththemarketingof risperdalinseptemberjpisettledwithofthestatesandthedistrictofcolumbianonmedicaidclaimsin connectionwiththesalesandmarketingofrisperdalandinvegaforatotalofapproximatelymillionan amountwhichhadbeenpreviouslyaccrue inthecompanysopiniontheultimateresolutionofanyoftheaboverisperdalmattersisnotexpectedtohavea materialadverseeffectonthecompanysfinancialpositionalthoughtheresolutioninanyreportingperiodcouldhavea materialimpactonthecompanysresultsofoperationsandcashflowsforthatperiod omnicare inseptemberjohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingdocumentsrelatedtothesalesandmarketingofeightdrugstoomnicareincomnicarea managerofpharmaceuticalbenefitsforlongtermcarefacilitiesinapriljohnsonjohnsonandcertainofit pharmaceuticalsubsidiarieswereservedintwocivilquitamcasesassertingclaimsunderthefederalfalseclaimsact andrelatedstatelawclaimsallegingthatthedefendantsprovidedomnicarewithrebatesandotherallegedkickback causingomnicaretofilefalseclaimswithmedicaidandothergovernmentprogramsinjanuarythegovernment johnsonjohnsonannualreportintervenedinbothofthesecasesnamingjohnsonjohnsonorthomcneiljanssenpharmaceuticalsincnowjanssen pharmaceuticalsincjpiandjohnsonjohnsonhealthcaresystemsincasdefendantssubsequentlythe commonwealthofmassachusettsvirginiaandkentuckyandthestatesofcaliforniaandindianaintervenedinthe actioninfebruarytheunitedstatesdistrictcourtforthedistrictofmassachusettsdismissedonequitamcase entirelyanddismissedtheothercaseinpartrejectingallegationsthatthedefendantshadviolatedtheirobligationto reportitsbestpricetohealthcareprogramofficialstheclaimsoftheunitedstatesandindividualstatesremain pendinginjunethepartiesweregrantedtheirjointmotiontostaythecasependingresolutionofthepotential settlementdiscussedintherisperdalsectionabove innovemberalawsuitwasfiledbyscottbartzaformeremployeeintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaagainstjohnsonjohnsonandcertainofitspharmaceuticalsubsidiariesthejj defendantsalongwithcodefendantsmckessoncorporationmckessonandomnicareincinfebruarythe plaintifffiledanamendedcomplaintthereafteronthejjdefendantsmotionthecasewastransferredtotheunite statesdistrictcourtforthedistrictofmassachusettswhereitiscurrentlypendingtheamendedcomplaintallegesa varietyofcausesofactionunderthefederalfalseclaimsactandcorrespondingstateandlocalstatutesincludingthat thejjdefendantsengagedinvariousimpropertransactionsthatwereallegedlydesignedtoreportfalseprescription drugpricestothefederalgovernmentinordertoreducethejjdefendantsmedicaidrebateobligationsthecomplaint furtherallegesthatthejjdefendantsimproperlyretaliatedagainsttheplaintiffforhavingraisedtheseallegation internallybartzseeksmultipleformsofreliefincludingdamagesandreinstatementtoapositionwiththesameseniority statusthejjdefendantssubsequentlymovedtodismissthecomplaintinmayinmarchthedistrictcourt dismissedbartzsclaimsunderthefederalfalseclaimsactanddeclinedtoexercisesupplementaljurisdictionover numerousrelatedclaimsunderstatefalseclaimsactstatutesthedistrictcourthoweverdeniedthedismissalmotion withregardtobartzsclaimsthathewasretaliatedagainstinviolationofthefederalfalseclaimsactandinviolationof newjerseysconscientiousemployeeprotectionactinfebruarythepartiesenteredintoasettlementagreement toresolveallofbartzsclaimsandfiledajointmotiontodismissthelawsuitwithprejudicethedistrictcourtgrantedthe motiontodismissallclaims mcneilconsumerhealthcare startinginjunemcneilconsumerhealthcaredivisionofmcneilppcincmcneilconsumerhealthcareand certainaffiliatesincludingjohnsonjohnsonthecompaniesreceivedgrandjurysubpoenasfromtheunitedstate attorneysofficefortheeasterndistrictofpennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvarious productsofmcneilconsumerhealthcareandthefdainspectionsofthefortwashingtonpennsylvaniaandlancaster pennsylvaniamanufacturingfacilitiesaswellascertaindocumentsrelatingtorecallsofasmallnumberofproductsof othersubsidiariesinadditioninfebruarythegovernmentservedmcneilppcincmcneilppcwithacivil investigativedemandseekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationofthefederalfalse claimsactthecompaniesarecooperatingwiththeunitedstatesattorneysofficeinrespondingtothesesubpoena thecompanieshavealsoreceivedcivilinvestigativedemandsfrommultiplestateattorneysgeneralofficesbroadly relatingtothemcneilrecallissuesthecompaniescontinuetocooperatewiththeseinquiriesinjanuarythe oregonattorneygeneralfiledacivilcomplaintagainstjohnsonjohnsonmcneilppcandmcneilhealthcarellcin statecourtallegingcivilviolationsoftheoregonunlawfultradepracticesactrelatingtoanearlierrecallofamcneilotc productinnovemberthestatecourtgrantedamotionbythecompaniestodismissoregonscomplaintinit entiretywithprejudiceindecemberoregonfiledanoticeofappealinthecourtofappealsofthestateof oregon inmarchtheunitedstatesfiledacomplaintforinjunctivereliefintheunitedstatesdistrictcourtfortheeastern districtofpennsylvaniaagainstmcneilppcandtwoofitsemployeesallegingthatmcneilppcisinviolationoffda regulationsregardingthemanufactureofdrugsatthefacilitiesitoperatesinlancasterpennsylvaniafortwashington pennsylvaniaandlaspiedraspuertoricoonthesamedaythepartiesfiledaconsentdecreeofpermanentinjunction resolvingtheclaimssetforthinthecomplaintthecourtapprovedandenteredtheconsentdecreeonmarch theconsentdecreewhichissubjecttoongoingenforcementbythecourtrequiresmcneilppctotakeenhance measurestoremediatethethreefacilitiesthefortwashingtonfacilitywhichwasvoluntarilyshutdowninaprilwill remainshutdownuntilathirdpartyconsultantcertifiesthatitsoperationswillbeincompliancewithapplicablelawand thefdaconcurswiththethirdpartycertificationthelancasterandlaspiedrasfacilitiesmaycontinuetomanufacture anddistributedrugsprovidedthatathirdpartyreviewsmanufacturingrecordsforselectedbatchesofdrugsrelease johnsonjohnsonannualreport fromthefacilitiesandcertifiesthatanydeviationsrevieweddonotadverselyaffectthequalityoftheselectedbatche mcneilppcsubmittedaworkplantothefdaforremediationofthelancasterandlaspiedrasfacilitiesandthatplan wasapprovedbythefdainoctoberthirdpartybatchrecordreviewmayceaseifthefdahasstatedthatthe facilitiesappeartobeincompliancewithapplicablelaweachfacilityissubjecttoafiveyearauditperiodbyathirdparty afterthefacilityhasbeendeemedbythefdatobeinapparentcompliancewithapplicablelaw injulysciosincsciosreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingdocumentsrelatedtothesalesandmarketingofnatrecorinaugustscioswa advisedthattheinvestigationwouldbehandledbytheunitedstatesattorneysofficeforthenortherndistrictof californiainsanfranciscoinfebruarytwoquitamcomplaintswereunsealedintheunitedstatesdistrictcourt forthenortherndistrictofcaliforniaallegingamongotherthingsimproperactivitiesinthepromotionofnatrecorin junetheunitedstatesgovernmentintervenedinoneofthequitamactionsandfiledacomplaintagainstsciosand johnsonjohnsonseekingreliefunderthefederalfalseclaimsactandassertingaclaimofunjustenrichmentin octoberthecriminalmatterwasresolvedthecivilcasehasbeenstayedpendingresolutionofthepotential settlementdiscussedintherisperdalsectionabove injunejohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrelatingtothemarketingofbiliarystentsbycordiscorporationcordisinfebruarythe governmentinformedcordisthatitwasclosingitsinvestigationinadditioninjanuaryacomplaintwasunsealedin theunitedstatesdistrictcourtforthenortherndistrictoftexasfiledbykevincolquittseekingdamagesagainstcordis andotherpartiesforallegedviolationsofthefederalfalseclaimsactandseveralsimilarstatelawsinconnectionwiththe marketingofbiliarystentstheunitedstatesdepartmentofjusticeandseveralstatesdeclinedtointerveneinjanuary thecourtgrantedcordissmotiontodismisstheclaimsagainstcordiswithprejudiceplaintiffhasappeale inseptembersynthesincsynthesreceivedacivilinvestigativedemandissuedpursuanttothefalseclaimsact fromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathedemandsoughtinformation regardingallegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproduct syntheshasproduceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry inoctobertheeuropeancommissionecannouncedthatitopenedaninvestigationconcerninganagreement betweenjanssencilagbvjanssencilagandsandozbvrelatingtothesupplyoffentanylpatchesinthenetherland andwhethertheagreementinfringeseuropeancompetitionlawinjanuarytheecissuedastatementof objectionssettingoutfactsregardingapotentialviolationofeuantitrustlawsjanssencilagispreparingaresponseto thestatementofobjection inapriljanssenpharmaceuticalsincjpireceivedaletterrequestingcertaindocumentsfromtheunitedstate departmentofjusticerelatingtothemarketingandpromotionofdoribaxjpihasprovideddocumentsandcontinue tocooperatewiththisgovernmentinquiry inmayacclarentincacclarentreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrequestingdocumentsbroadlyrelatingtothesalesmarketingandpromotionbyacclarentofrelieva stratusmicroflowspacerproductsacclarentiscooperatingwiththeunitedstatesattorneysofficeinresponde tothesubpoena inaugustdepuyorthopaedicsincdepuyincnowdepuysynthesincdepuysynthesandjohnson johnsonservicesincreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticefortheproductionofmaterialsrelatingto theasrxlhipdevicethegovernmenthassincemadeadditionalinformalrequestsfortheproductionofdocumentsas tothedevicethegovernmentisinvestigatingwhetheranypersonorentitysubmittedorcausedtobesubmittedfalse claimsorfalsestatementsaffectingfederalhealthcareprogramsinconnectionwiththemarketinganduseoftheasrxl hipdevicedepuyorthopaedicsincdepuysynthesandjohnsonjohnsonservicesinchavevoluntarilyproduce documentsinresponsetothegovernmentsinformalrequestsandarefullycooperatingwiththegovernmentscivil investigation inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonsubsidiariesjohnsonjohnsonanditssubsidiarieshavesinceenteredintoatollingagreementwith thestatesparticipatinginthemultistateinvestigation johnsonjohnsonannualreportindecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtssystemduringtheperiodtothepresentthe unitedstatesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelatetothe investigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpocdandjohnson johnsonretaincertainliabilitiesthatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakos andhavetakenappropriatestepstoretainpotentiallyrelevantdocumentsandwillcooperatewiththeunitedstate attorneysofficesinvestigationwithrespecttosuchactivity inrecentyearsjohnsonjohnsonhasreceivednumerousrequestsfromavarietyofunitedstatescongressional committeestoproduceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsonto cooperatewiththeseinquiriesbyproducingtherequestedinformation generallitigation startinginjulyfivelawsuitswerefiledinunitedstatesdistrictcourtforthedistrictofnewjerseybyvarious employersandemployeebenefitplansandfundsseekingtorecoveramountstheypaidforrisperdalforplan participantsingeneralplaintiffsallegethatjohnsonjohnsonandcertainofitspharmaceuticalsubsidiariesengagedin offlabelmarketingofrisperdalinviolationofthefederalandnewjerseyricostatutesinadditionplaintiff assertedvariousstatelawclaimsallofthecaseswereconsolidatedintoonecaseseekingclassactionstatusbutshortly thereafteroneactionwasvoluntarilydismissedindecemberthecourtdismissedtheactionsofthefourremaine plaintiffsinaprilthoseplaintiffsfiledanewconsolidatedclassactionagainstjohnsonjohnsonandjanssenlp nowjanssenpharmaceuticalsincandinmarchthatactionwasdismissedinapriloneofthoseplaintiff filedanoticeofappealwiththeunitedstatescourtofappealsforthethirdcircuitthatappealwasdismissedinjuly inaprilorthoclinicaldiagnosticsincocdreceivedagrandjurysubpoenafromtheunitedstatesdepartment ofjusticeantitrustdivisionrequestingdocumentsandinformationfortheperiodbeginningseptemberthrough thepresentpertainingtoaninvestigationofallegedviolationsoftheantitrustlawsinthebloodreagentsindustryocd compliedwiththesubpoenainfebruaryocdreceivedaletterfromtheantitrustdivisionindicatingthatithad closeditsinvestigationinnovemberinjunefollowingthepublicannouncementthatocdhadreceiveda grandjurysubpoenamultipleclassactioncomplaintswerefiledagainstocdbydirectpurchasersseekingdamagesfor allegedpricefixingthevariouscaseswereconsolidatedforpretrialpurposesintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaasinrebloodreagentantitrustlitigationinaugustthedistrictcourtgranteda motionfiledbyplaintiffsforclasscertificationocdrequestedinterlocutoryreviewoftheclasscertificationdecisionand inoctobertheappellatecourtgrantedocdspetitionforinterlocutoryreview inaprilaputativeclassactionlawsuitwasfiledintheunitedstatesdistrictcourtforthenortherndistrictof californiabyrepresentativesofnursinghomeresidentsortheirestatesagainstjohnsonjohnsonomnicareinc omnicareandotherunidentifiedcompaniesorindividualsinfebruaryplaintiffsfiledasecondamendedcomplaint assertingthatcertainrebateagreementsbetweenjohnsonjohnsonandomnicareincreasedtheamountofmoneyspent onpharmaceuticalsbythenursinghomeresidentsandviolatedtheshermanactandthecaliforniabusinessprofession codethesecondamendedcomplaintalsoassertedaclaimofunjustenrichmentplaintiffssoughtmultipleformsof monetaryandinjunctivereliefjohnsonjohnsonmovedtodismissthesecondamendedcomplaintinmarchthe courtgrantedthemotioninitsentiretyinaugustdismissingallclaimsassertedbyplaintiffsinoctoberthe courtdismissedtheactionwithprejudicetheplaintiffsfiledanoticeofappealtotheunitedstatescourtofappealsfor theninthcircuitinnovemberinfebruaryplaintiffsstipulatedtoavoluntarydismissalofthematterwith prejudicepursuanttothetermsofthestipulationtheninthcircuitdismissedthecaseinitsentiretyinmarch startinginmaymultiplecomplaintsseekingclassactioncertificationrelatedtothemcneilrecallshavebeenfile againstmcneilconsumerhealthcareandcertainaffiliatesincludingjohnsonjohnsonintheunitedstatesdistrictcourt fortheeasterndistrictofpennsylvaniathenortherndistrictofillinoisthecentraldistrictofcaliforniathesoutherndistrict ofohioandtheeasterndistrictofmissouritheseconsumercomplaintsallegegenerallythatpurchasersofvariousmcneil medicinesareowedmonetarydamagesandpenaltiesbecausetheypaidpremiumpricesfordefectivemedicationsrather thanlessexpensivealternativemedicationsallbutonecomplaintseekscertificationofanationwideclassofpurchasersof thesemedicineswhereasonecomplainttheharveycaseseekscertificationofaclassofmotrinibpurchasersin missouriinoctoberthejudicialpanelonmultidistrictlitigationconsolidatedalloftheconsumercomplaintsexcept fortheharveycasewhichwasconsolidatedinmarchintoonelawsuitinremcneilconsumerhealthcareetal johnsonjohnsonannualreport marketingandsalespracticeslitigationforpretrialproceedingsintheunitedstatesdistrictcourtfortheeasterndistrict ofpennsylvaniainjanuarytheplaintiffsinallofthecasesexcepttheharveycasefiledaconsolidatedamendedcivil consumerclassactioncomplaintcacnamingadditionalpartiesandclaimsinjulythecourtgrantedamotionby johnsonjohnsontodismissthecacwithoutprejudicebutpermittedtheplaintiffstofileanamendedcomplaintwithin thirtydaysofthedismissalorderinaugusttheplaintiffsfiledasecondamendedcivilconsumerclassaction complaintsacinjulythecourtgrantedjohnsonjohnsonsmotiontodismissthesacwithprejudice separatelyinseptemberjohnsonjohnsonjohnsonjohnsonincandmcneilconsumerhealthcaredivisionof johnsonjohnsonincreceivedanoticeofcivilclaimfiledbynickfieldinthesupremecourtofbritishcolumbia canadathebccivilclaimthebccivilclaimisaputativeclassactionbroughtonbehalfofpersonswhoresidein britishcolumbiaandwhopurchasedduringtheperiodbetweenseptemberandthepresentoneormore variousmcneilinfantsorchildrensoverthecountermedicinesthatweremanufacturedatthefortwashingtonfacility thebccivilclaimallegesthatthedefendantsviolatedthebcbusinesspracticesandconsumerprotectionactand othercanadianstatutesandcommonlawsbysellingmedicinesthatwereallegedlynotsafeandoreffectiveordidnot complywithcanadiangoodmanufacturingpracticesthebcplaintiffservedtheiraffidavitsinsupportofclass certificationinaprilthedefendantsrespondingaffidavitswereservedinjunethedateforhearingofthe certificationapplicationhasnotyetbeenschedule inseptemberashareholderronaldmonkfiledalawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyseekingclasscertificationandallegingthatjohnsonjohnsonandcertainindividualsincludingexecutiveofficer andemployeesofjohnsonjohnsonfailedtodisclosethatanumberofmanufacturingfacilitiesfailedtomaintaincurrent goodmanufacturingpracticesandthatasaresultthepriceofthecompanysstockdeclinedsignificantlyplaintiffseek topursueremediesunderthesecuritiesexchangeactoftorecoverhisallegedeconomiclossesindecember amotionbyjohnsonjohnsontodismisswasgrantedinpartanddeniedinpartplaintiffmovedthecourtto reconsiderpartofthedecemberrulingdefendantsfiledanswerstotheremainingclaimsoftheamende complaintinfebruaryandthecaseisproceedingtodiscoveryinmaythecourtdeniedplaintiffsmotionfor reconsiderationinseptemberplaintifffiledasecondamendedcomplaintandjohnsonjohnsonhasmovedto dismissplaintiffssecondamendedcomplaintinpart inaprilomjpharmaceuticalsincomjprfiledalawsuitagainsttheunitedstatesinunitedstatesdistrictcourt forthedistrictofpuertoricoallegingoverpaymentoffederalincometaxesforthetaxyearsendednovember andnovemberomjprallegesthattheinternalrevenueserviceerroneouslycalculatedomjprstaxcredits undersectionofthetaxcodeomjprfiledamotionforsummaryjudgmentandtheunitedstatesfiledacross motionforsummaryjudgmentinoctoberthecourtgrantedtheunitedstatesmotionforsummaryjudgmentand deniedomjprsmotionforsummaryjudgmentomjprappealedthisdecisionifomjprlosesthislawsuititmayface liabilityforsubsequenttaxyear inaugustanarbitrationpanelruledthatmitsubishitanabepharmacorporationtanabejanssenbiotechincs jbisdistributorofremicadeinjapancouldseektomodifytheproportionofnetsalesrevenuethattanabemust remittojbiinexchangefordistributionrightsandcommercialsupplyofremicadethesupplypricetanabe commencedthearbitrationagainstcentocororthobiotechincnowjbiinpursuanttothepartiesdistribution agreementwhichgrantstanabetherighttodistributeremicadeinjapanandcertainotherpartsofasiajbihas counterclaimedforanincreaseinthesupplypriceahearingwasheldinnovembertodeterminetheappropriate splitofrevenueandthepartiesareawaitingadecision johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation shareholderderivativeaction startinginaprilanumberofshareholderderivativelawsuitswerefiledintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstcertaincurrentandformerdirectorsandofficersofjohnsonjohnsonjohnsonjohnson isnamedasanominaldefendanttheseactionswereconsolidatedinaugustintoonelawsuitinrejohnson johnsonderivativelitigationadditionallyinseptemberanothershareholderderivativelawsuitwasfiledbymichael wolininnewjerseysuperiorcourtagainstcertaincurrentandformerdirectorsandofficersofjohnsonjohnson johnsonjohnsonisnamedasanominaldefendantinthisactionaswellthepartiestothisactionhavestipulatedthatit shallbestayeduntiltheinrejohnsonjohnsonderivativelitigationiscompletelyresolve johnsonjohnsonannualreporttheseshareholderderivativeactionsaresimilarintheirclaimsandcollectivelytheyassertavarietyofallegedbreachesof fiduciarydutiesincludingamongotherthingsthatthedefendantsallegedlyengagedinapprovedoforfailedtoremedy orpreventdefectivemedicaldevicesimproperpharmaceuticalrebatesimproperofflabelmarketingofpharmaceutical andmedicaldeviceproductsviolationsofcurrentgoodmanufacturingpracticeregulationsthatresultedinproductrecalls andthattheyfailedtodisclosetheaforementionedallegedmisconductinthecompanysfilingsunderthesecuritie exchangeactofeachcomplaintseeksavarietyofreliefincludingmonetarydamagesandcorporategovernance reformsjohnsonjohnsonmovedtodismisstheseactionsonthegroundsinteraliathattheplaintiffsfailedtomakea demandupontheboardofdirectorsinseptemberinrejohnsonjohnsonderivativelitigationwasdismisse withoutprejudiceandwithleavetofileanamendedcomplaint johnsonjohnsonfiledareportintheinrejohnsonjohnsonderivativelitigationmatterinjulypreparedbya specialcommitteeoftheboardofdirectorswhichinvestigatedtheallegationscontainedinthederivativeactionsandin anumberofshareholderdemandlettersthattheboardreceivedinraisingsimilarissuesthespecialcommittee wasassistedinitsinvestigationbyindependentcounselthespecialcommitteesreportrecommendedithatjohnson johnsonrejecttheshareholderdemandsandtakewhateverstepsarenecessaryorappropriatetosecuredismissalofthe derivativelitigationandiithattheboardofdirectorscreateanewregulatoryandcompliancecommitteechargedwith responsibilityformonitoringandoversightofthecompanyshealthcarecomplianceandqualitycompliancesystems andissuestheboardofdirectorsofjohnsonjohnsonunanimouslyadoptedthespecialcommittees recommendationsandinapriltheboardofdirectorscreatedtheregulatorycompliancegovernmentaffairs committee inaugusttwoshareholderswhohadsubmittedshareholderdemandlettersinfiledshareholderderivative lawsuitsintheunitedstatesdistrictcourtforthedistrictofnewjerseynamingvariouscurrentandformerofficersand directorsasdefendantsandchallengingtheboardsrejectionoftheirdemandsinnovemberthecourt consolidatedthesetwocasesintocopelandvprincejohnsonjohnsonsecuredanextensionoftimetorespondtothe complaint twoadditionalshareholderderivativelawsuitswerefiledinmayintheunitedstatesdistrictcourtforthedistrictof newjerseyandtwoothershareholderderivativelawsuitswerefiledinnewjerseysuperiorcourtinmayand augustallnamingcurrentdirectorsofjohnsonjohnsonasdefendantsandjohnsonjohnsonasthenominal defendantthecomplaintsallegebreachesoffiduciarydutiesrelatedtothecompanyscompliancewiththeforeign corruptpracticesactandparticipationintheunitednationsiraqoilforfoodprogramthatthecompanyhassuffered damagesasaresultofthoseallegedbreachesandthatthedefendantsfailedtodisclosetheallegedmisconductinthe companysfilingsunderthesecuritiesexchangeactofplaintiffsseekmonetarydamagesandthestatecourt plaintiffsalsoseekcorporategovernancereformsthefederallawsuitswereconsolidatedinjulyintoinrejj fcpaderivativeshareholderlitigationandanamendedconsolidatedcomplaintwasfiledinaugustinoctober johnsonjohnsonmovedtodismisstheconsolidatedfederallawsuitonthegroundsthattheplaintiffsfailedto makeademandupontheboardofdirectorstheplaintiffssecuredanextensionoftimetorespondtothemotionthe statelawsuitswereconsolidatedinnovemberintoinrejjshareholderderivativelitigationandaconsolidated complaintwasfiledindecemberinjanuaryjohnsonjohnsonmovedtodismissorstaythestatelawsuit pendingresolutionofthefederallawsuitandmovedtodismissonthegroundthattheplaintiffsfailedtomakeademandon theboardofdirectorsinmaythecourtgrantedamotionbyjohnsonjohnsontostaythestatelawsuitspending resolutionofinrejjfcpaderivativeshareholderlitigation injulythepartiesineachoftheshareholderderivativecasespendinginfederalcourtdiscussedabovespecifically inrejohnsonjohnsonderivativelitigationcopelandvprinceandinrejjfcpaderivativeshareholderlitigation filedastipulationofsettlementtopermanentlyresolvealloftheactionsintheirentiretyinoctoberthesettlement wasapprovedbythecourtinnovemberanoticeofappealwasfiledintheunitedstatescourtofappealsforthe thirdcircuitbyashareholderwhoobjectedtotheapprovalofthesettlementinthedistrictcourtonthegroundsthatthe lawsuitandthesettlementdidnotprovideanybenefittothecompanyandthatplaintiffscounselhadrequestedan excessivefeeaward injunetwoothershareholderswhohadsubmittedashareholderdemandletterinmarchthenewjersey buildinglaborersannuityandthenewjerseybuildinglaborerspensionfundsfiledanadditionalshareholderderivative lawsuitinnewjerseysuperiorcourtnamingvariouscurrentandformerofficersanddirectorsasdefendantsandalso challengingtheboardsrejectionoftheirdemandsthisshareholderderivativelawsuitpurportstoallegethesameclaim thatarethesubjectofthesettlementdescribedabovethepartiestothisactionhadenteredintoaconsentorderstaying theactionpendingfinalapprovalofthesettlementdiscussedaboveinnovembertheplaintiffsagreedtovoluntarily dismisstheaction johnsonjohnsonannualreport inseptembertwoadditionalshareholderderivativelawsuitswerefiledintheunitedstatesdistrictcourtforthe districtofnewjerseybydonovanspamerandthegeorgeleonfamilytrustnamingcurrentdirectorsandoneformer directorofjohnsonjohnsonasdefendantsandjohnsonjohnsonasthenominaldefendanttheselawsuitsallegethat thedefendantsbreachedtheirfiduciarydutiesintheirdecisionswithrespecttothecompensationofthechiefexecutive officerduringtheperiodfromthroughandthatthedefendantsmademisleadingstatementsinthe companysannualproxystatementsbothoftheselawsuitshavebeenvoluntarilydismissedwithoutprejudicebuta similarlawsuitonbehalfofthegeorgeleonfamilytrustwasrefiledinjulythatlawsuitseeksavarietyofrelief includingmonetarydamagesinjunctivereliefandcorporategovernancereformstheabovesettlementdoesnotresolve thesepotentialclaimstheboardofdirectorsevaluationoftheseallegationsisongoe restructure incordiscorporationasubsidiaryofjohnsonjohnsonannouncedthediscontinuationofitsclinicaldevelopment programforthenevosirolimuselutingcoronarystentandcessationofthemanufactureandmarketingofcypher andcypherselectplussirolimuselutingcoronarystentsbytheendofthecompanywillfocusonother cardiovasculartherapieswheresignificantpatientneedsexist asaresultoftheabovementionedrestructuringplanannouncedbycordiscorporationthecompanyrecorde millioninrelatedpretaxchargesofwhichapproximatelymillionofthepretaxrestructuringchargesrequirecash paymentsthemillionofrestructuringchargesconsistsofassetwriteoffsofmillionandmillionrelate toleaseholdandcontractobligationsandotherexpensesthemillionofassetwriteoffsrelatetopropertyplantand equipmentofmillionintangibleassetsofmillionandinventoryofmillionrecordedincostofproduct soldthecordisrestructuringprogramhasbeensubstantiallycompletedtherestructuringchargewasrecordedinthe medicaldevicesanddiagnosticssegment johnsonjohnsonannualreportreport independent register public accounting firm totheshareholdersandboardofdirectorsofjohnsonjohnson inouropiniontheaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearning statementsofcomprehensiveincomestatementsofequityandstatementsofcashflowspresentfairlyinallmaterial respectsthefinancialpositionofjohnsonjohnsonanditssubsidiariesatdecemberandjanuaryand theresultsoftheiroperationsandtheircashflowsforeachofthethreeyearsintheperiodendeddecemberin conformitywithaccountingprinciplesgenerallyacceptedintheunitedstatesofamericaalsoinouropinionthe companymaintainedinallmaterialrespectseffectiveinternalcontroloverfinancialreportingasofdecember basedoncriteriaestablishedininternalcontrolintegratedframeworkissuedbythecommitteeofsponsore organizationsofthetreadwaycommissioncosothecompanysmanagementisresponsibleforthesefinancial statementsformaintainingeffectiveinternalcontroloverfinancialreportingandforitsassessmentoftheeffectivenessof internalcontroloverfinancialreportingincludedintheaccompanyingmanagementsreportoninternalcontrolover financialreportingourresponsibilityistoexpressopinionsonthesefinancialstatementsandonthecompanysinternal controloverfinancialreportingbasedonourintegratedauditsweconductedourauditsinaccordancewiththestandard ofthepubliccompanyaccountingoversightboardunitedstatesthosestandardsrequirethatweplanandperform theauditstoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementand whethereffectiveinternalcontroloverfinancialreportingwasmaintainedinallmaterialrespectsourauditsofthefinancial statementsincludedexaminingonatestbasisevidencesupportingtheamountsanddisclosuresinthefinancial statementsassessingtheaccountingprinciplesusedandsignificantestimatesmadebymanagementandevaluatingthe overallfinancialstatementpresentationourauditofinternalcontroloverfinancialreportingincludedobtainingan understandingofinternalcontroloverfinancialreportingassessingtheriskthatamaterialweaknessexistsandtesting andevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalso includedperformingsuchotherproceduresasweconsiderednecessaryinthecircumstanceswebelievethatouraudit provideareasonablebasisforouropinion acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounte principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statement becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate asdescribedinmanagementsreportoninternalcontroloverfinancialreportingmanagementhasexcludedsynthe incfromitsassessmentofinternalcontroloverfinancialreportingasofdecemberbecauseitwasacquiredby thecompanyinapurchasebusinesscombinationduringwehavealsoexcludedsynthesincfromourauditof internalcontroloverfinancialreportingsynthesincisawhollyownedsubsidiarywhosetotalassetsandtotalrevenues representapproximatelyandrespectivelyoftherelatedconsolidatedfinancialstatementamountsasofandfor theyearendeddecember pricewaterhousecoopersllp newyorknewyork february johnsonjohnsonannualreport management report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciple internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofdecemberinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframeworkthese criteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunicationand monitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignandoperate effectivenessofitsinternalcontrolsoverfinancialreporte thecompanyacquiredsynthesincanditsconsolidatedsubsidiariessynthesinjunesynthestotalasset whichwereprimarilyintangibleassetsandgoodwillandtotalrevenuesrepresentedapproximatelyand respectivelyoftherelatedconsolidatedfinancialstatementsasofandfortheperiodendeddecemberasthe acquisitionoccurredinjuneandsyntheswaspreviouslynotsubjecttotherequirementsundersectionofthe sarbanesoxleyactofthescopeofthecompanysassessmentofthedesignandeffectivenessofinternalcontrol overfinancialreportingforthefiscalyearexcludedsynthesthisexclusionisinaccordancewiththesecsgeneral guidancethatanassessmentofarecentlyacquiredbusinessmaybeomittedfromthescopeintheyearofacquisition basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof decemberthecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofdecemberhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappear alexgorsky dominicjcaruso chairmanboardofdirector vicepresidentfinance chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreportsummary operation statistical datum dollarsinmillionsexceptpershare amount salestocustomersus salestocustomersinternational totalsale costofproductssold sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalized otherincomeexpensenet restructure earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearning addnetlossattributabletononcontrollinginter netearningsattributableto johnsonjohnson percentofsalestocustomer dilutednetearningspershareofcommonstock percentreturnonaverageshareholdersequity percentincreasedecreaseover previousyear salestocustomer dilutednetearningspershare supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalasset longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillion basic diluted employeesthousand attributabletojohnsonjohnson johnsonjohnsonannualreport shareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinveste year cumulative total shareholder return johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year cumulative total shareholder return johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreportboard director senior management alexgorsky alexgorsky chairmanboardofdirector chiefexecutiveofficer chairmanexecutivecommittee marysuecoleman charleseaustin presidentuniversityofmichigan vicepresidentglobalsupplychain jamesgcullen dominicjcaruso retiredpresidentandchiefoperatingofficer vicepresidentfinance bellatlanticcorporation chieffinancialofficer ianeldavis memberexecutivecommittee senioradvisorapaxpartnersformerchairmanand douglaskchia worldwidemanagingdirectormckinseycompany corporatesecretary assistantgeneralcounsel michaelmejohns professoremoryschoolofmedicineandrollin stephenjcosgrove schoolofpublichealthchancellorandexecutive corporatecontroller vicepresidentofhealthaffairsemeritusemory chiefaccountingofficer university joaquinduato susanllindquist worldwidechairmanpharmaceuticalsgroup memberandformerdirectorwhiteheadinstitutefor petermfasolo biomedicalresearchprofessorofbiology vicepresidentglobalhumanresource massachusettsinstituteoftechnology memberexecutivecommittee annemmulcahy karenalicitra formerchairmanandchiefexecutiveofficer worldwidechairmanglobalmedicalsolutionsgroup xeroxcorporation michelorsinger leofmullin worldwidechairmanglobalorthopaedicsgroup retiredchairmanandchiefexecutiveofficer deltaairlinesinc johnapapa treasurer williamdperez senioradvisorgreenhillcoincretiredpresident sandraepeterson andchiefexecutiveofficerwmwrigleyjrcompany groupworldwidechairman memberexecutivecommittee charlesprince retiredchairmanandchiefexecutiveofficer garyjpruden citigroupinc worldwidechairmanglobalsurgerygroup michaelesnee davidsatcher vicepresidentglobalcorporateaffair directorcenterofexcellenceonhealthdisparitie directorsatcherhealthleadershipinstituteand paulusstoffel poussaintsatchercosbychairinmentalhealth chiefscientificofficer morehouseschoolofmedicine worldwidechairmanpharmaceuticalsgroup memberexecutivecommittee aeugenewashington vicechancellorofhealthsciencesdeanofthedavid michaelhullmann geffenschoolofmedicineattheuniversityofcalifornia vicepresidentgeneralcounsel losangelesuclachiefexecutiveofficerofthe memberexecutivecommittee uclahealthsystem jessejwu ronaldawilliam worldwidechairmanconsumergroup formerchairmanandchiefexecutiveofficer aetnaincprincipaloffice commonstock johnsonjohnsonontheweb onejohnsonjohnsonplaza listedonnewyorkstockexchange ourwebsitewwwjnjcom newbrunswicknewjersey stocksymboljnj shareholderrelationscontact ourcompanyblogwwwjnjbtwcom annualmeete douglaskchia theannualmeetingofshareholderswilltake corporatesecretary ourhistoryblogwwwkilmerhousecom placeonthursdayaprilatthe hyattregencyhoteltwoalbanystreetnew investorrelationscontact wwwfacebookcomjnj brunswicknewjerseythemeetingwill conveneatamallshareholdersasofthe louisemehrotra recorddateoffebruaryarecordially vicepresidentinvestorrelations wwwtwittercomjnjcare invitedtoattendaformalnoticeofannual wwwtwittercomjnjnews meetingproxystatementandproxyhave wwwyoutubecomuserjnjhealth beensenttoshareholder transferagentandregistrar wwwyoutubecomuserjnjenntv corporategovernance questionsregardingstockholdingscertificate wwwlinkedincomcompany copiesofourannualreporton replacementtransferdividendsandaddress johnsonjohnson formkquarterlyreportsonformq changesshouldbedirectedto andcurrentreportsonformktothe computersharetrustcompanyna securitiesandexchangecommissionproxy royallstreet toviewthejohnsonjohnsonannualreport statementandthisannualreportare cantonma pleasegotowwwannualreportjnjcom availableonlineatwwwinvestorjnjcom orscanthisqrcode secfilingscfmortoshareholderswithout outsidetheus chargeuponwrittenrequesttothesecretary wwwcomputersharecom atourprincipaladdressorbycalle dividendreinvestmentplan theplanallowsforfullorpartialdividend inadditiononthecorporategovernance reinvestmentandadditionalmonthlycash sectionofourwebsitewwwinvestorjnjcom investmentsuptoperyearin shareholderscanviewourrestatedcertificate johnsonjohnsoncommonstockwithout ofincorporationbylawsprinciplesof brokeragecommissionsorservicechargeson corporategovernancechartersoftheaudit stockpurchasesifyouareinterestedin committeecompensationbenefit participatingintheplanandneedan committeenominatingcorporate authorizationformandormoreinformation governancecommitteeregulatory pleasecallcomputersharetrustcompany compliancegovernmentaffair naator committeeandsciencetechnology outsidetheus sustainabilitycommitteepolicyonbusiness conductforemployeescodeofbusiness hearingimpaired conductethicsformembersoftheboard shareholderswhohaveinquiriesregarde ofdirectorsandexecutiveofficersandother stockrelatedmatterscancommunicate corporategovernancematerialscopiesof directlywithcomputersharetrustcompany thesedocumentsareavailabletoshareholder naviaatelecommunicationsdevicetdd withoutchargeuponwrittenrequesttothe thetelephonenumberforthisserviceis secretaryatourprincipaladdres oroutsidethe undersectionofthesarbanesoxleyact wearerequiredtofilecertificationssignedby electronicdeliverynotification thechiefexecutiveofficerandthechief theproxystatementandourannual financialofficerasexhibitstoourformk reportareavailableonourwebsiteat orformqforeachfiscalyearorquart wwwinvestorjnjcomannualreportscfm inadditionwearerequiredtosubmita insteadofreceivingpapercopiesofnextyear certificationsignedbythechiefexecutive proxystatementandannualreportbymail officertothenewyorkstockexchange youcanelecttoreceiveanemailmessagethat withindaysfollowingtheannualmeete willprovidealinktothosedocumentsonthe ofshareholderscopiesofthecertification internetshareholderswhoholdtheirshare filedforpreviousyearsarepostedonthe intheirownnamemayenrollintheelectronic corporategovernancesectionofourwebsite proxyandannualreportaccessservicefor andfuturecertificationswillbeposte futureannualmeetingsofshareholder promptlyuponfile onlineatwwwcomputersharenacomgreen shareholdersthatholdtheirsharesinstreet namethatisinthenameofabankbroker thejohnsonjohnsonannualreportcontainsmanyof orotherholderofrecordwhowishtoenroll thevaluabletrademarksandtradenamesownedanduse forelectronicaccessmayregisterforonline bythejohnsonjohnsonfamilyofcompaniesinthe deliveryofmaterialsbygoingto unitedstatesandinternationallytodistinguishproduct enrollicsdelivercomjnj andservicesofoutstandingquality johnsonjohnson shareholder informationour credo believe responsibility istothe doctorsnurse patient tomother father whouse product service inmeete need wedo high quality constantly strivetoreduce costsin order maintain reasonable price customersorder service promptly accurately supplier distributor opportunity tomake afair profit responsible toour employee man woman whowork withusthroughout worldeveryone consider asan individual respect dignity recognize merit asense security jobscompensation fair adequate working condition clean orderly safewe mindful waystohelp employee fulfill family responsibility employee feel free tomake suggestion complaint equal opportunity employment development advancement thosequalifie provide competent management action justand ethical responsible tothe community welive workand tothe world community aswell good citizen support good worksand charity bear fair share taxeswe encourage civic improvement well health education maintain good order property weare privileged touse protect environment natural resource final responsibility istoour stockholder businessmust sound profit experiment withnew idea research carry oninnovative program develop mistake pay fornew equipment purchase new facility provide new product launch reserve create toprovide adverse timeswhen weoperate accord tothese principle stockholder realize afair return onejohnsonjohnsonplazanewbrunswicknewjersey